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Soft tissue sarcomas (STS) are a group of malignancies that arise from mesenchymal tissue, consisting
of over 50 distinct histiologic subtypes. Unfortunately, the five-year survival rate of sarcoma patients has
remained relatively unchanged, and due to the rarity of the disease, research and development of
adequate therapeutics for STS lags behind other cancers. Therefore, understanding the molecular drivers
of STS is important in developing new therapeutics, as well as discovering druggable processes that
occur across multiple subtypes. One feature common to STS is hypoxia, or low O2 conditions. Using
molecular biology, biochemical approaches, genetically engineered mouse models, as well as querying
publically available data sets, we determined that Hypoxia Inducible Factor (HIF)-2α suppresses
fibrosarcoma, dedifferentiated liposarcoma, and undifferentiated pleomorphic sarcoma (UPS) growth in
vivo. In addition, we found that STS patient samples express low levels of EPAS1 (the gene encoding
HIF-2α). Our results showed increased levels of the calcium activated chloride channel ANO1, in HIF-2α
deficient UPS tumors, which increased mTORC1 activity. Additionally, we determined that HIF-2α was
epigenetically silenced in STS, and could be re-expressed with histone deacetylation inhibitor (HDACi)
treatment. HDACi suppressed STS growth in vivo in a HIF-2α dependent manner. Moreover, we
established that autophagy promotes fibrosarcoma and UPS survival under hypoxic and ischemic-like
conditions. Autophagic inhibition, either with chloroquine or the more potent autophagy inhibitor Lys05,
reduces UPS and fibrosarcoma growth in vitro and in vivo. From these studies, future clinical studies are
warranted to test histone deacetylase inhibitors and autophagy inhibitors in patients with the STS
subtypes examined here.
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ABSTRACT
TARGETING STRESS RESPONSE PATHWAYS IN SOFT TISSUE SARCOMA: THE ROLE OF
HYPOXIA AND AUTOPHAGY IN TUMOR SURVIVAL
Michael Sachio Nakazawa
Dr. M. Celeste Simon

Soft tissue sarcomas (STS) are a group of malignancies that arise from mesenchymal
tissue, consisting of over 50 distinct histiologic subtypes. Unfortunately, the five-year
survival rate of sarcoma patients has remained relatively unchanged, and due to the
rarity of the disease, research and development of adequate therapeutics for STS lags
behind other cancers. Therefore, understanding the molecular drivers of STS is
important in developing new therapeutics, as well as discovering druggable processes
that occur across multiple subtypes. One feature common to STS is hypoxia, or low O2
conditions. Using molecular biology, biochemical approaches, genetically engineered
mouse models, as well as querying publically available data sets, we determined that
Hypoxia Inducible Factor (HIF)-2α suppresses fibrosarcoma, dedifferentiated
liposarcoma, and undifferentiated pleomorphic sarcoma (UPS) growth in vivo. In
addition, we found that STS patient samples express low levels of EPAS1 (the gene
encoding HIF-2α). Our results showed increased levels of the calcium activated chloride
channel ANO1, in HIF-2α deficient UPS tumors, which increased mTORC1 activity.
Additionally, we determined that HIF-2α was epigenetically silenced in STS, and could
be re-expressed with histone deacetylation inhibitor (HDACi) treatment. HDACi
suppressed STS growth in vivo in a HIF-2α dependent manner. Moreover, we
established that autophagy promotes fibrosarcoma and UPS survival under hypoxic and
ischemic-like conditions. Autophagic inhibition, either with chloroquine or the more
potent autophagy inhibitor Lys05, reduces UPS and fibrosarcoma growth in vitro and in
iv

vivo. From these studies, future clinical studies are warranted to test histone deacetylase
inhibitors and autophagy inhibitors in patients with the STS subtypes examined here.
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CHAPTER 1: Introduction

Part I: Soft tissue sarcoma and hypoxia: friend or foe?
A. Soft tissue sarcomas and the hypoxic response
Soft tissue sarcomas (STS) are a rare, but diverse group of malignancies that are
believed to originate from mesenchymal tissue, such as fat, cartilage, connective tissue,
and muscle. There are over 50 distinct histologic STS subtypes1. However, due to the
rarity of these cancers, as well as the multitude of subtypes driven by different molecular
and genetic alterations, research and development of adequate therapeutics for these
diseases lags behind other cancers, and these malignancies remain relatively
understudied2. Of these subtypes, undifferentiated pleomorphic sarcoma (UPS),
fibrosarcoma, and dedifferentiated liposarcoma (DD-LPS) are of particular interest, as
they are all high-grade, undifferentiated STS that together represent up to 40% of newly
diagnosed sarcoma cases in adults3.
Although STS are driven by different molecular mechanisms depending on their
subtype, one feature common among many high-grade subtypes is that there are large
areas of significant hypoxia, or low oxygen tension. This is partly due to their rapid
proliferation and size4,5. Importantly, hypoxia in STS patient samples and mouse models
has been associated with lower overall survival and disease-free survival5,6, and so it is
critical to understand how hypoxic conditions affect STS development.
Cancer cells under these hypoxic and/or ischemic conditions utilize oxygensensing pathways to adapt to the stresses of the tumor microenvironment. Additionally,
hypoxia correlates with therapeutic resistance, both to cytotoxic chemotherapeutics and
1

radiation therapy7. While various cellular pathways are used to adapt to hypoxia, the
hypoxia inducible factors (HIFs) function as key modulators of gene regulation under
hypoxic stress. The HIFs consist of 3 isoforms (HIF-1α, HIF-2α, and HIF-3α)8-10, with
HIF-1α and HIF-2α being the most well-studied, and HIF-3α consisting of multiple splice
variants11. Under hypoxia, the oxygen labile HIF-α subunits heterodimerize with the
stable HIF-1β subunit (also known as ARNT), and in the case of HIF-1α/-2α, this
heterodimer binds to HIF-response elements (HREs) across the genome to promote
gene expression12,13 (Fig. 1).
Using high-throughput approaches, several hundred genes have now been
demonstrated to be regulated by HIF-1α, HIF-2α, or both14. Although the hypoxia
response element recognized by both HIFα subunits is the same (RCGTG), aminoterminal transactivation domains (N-TAD) in the subunits appear to give transcriptional
specificity15. Recently, much attention has focused on identifying metabolic alterations
driven by HIFs in cancer. Although the HIFs were initially thought to function primarily
through their angiogenic and oxygen homeostatic mechanisms in cancer16, an
increasing body of evidence has also shown the importance of HIF driven alterations of
metabolic pathways supporting tumor growth.
B. HIF-1α versus HIF-2α in cancer
Although both HIF-1α and HIF-2α are activated under hypoxic conditions, and
they can regulate a set of overlapping genes, many important HIF targets are controlled
specifically by one isoform or the other17-19. For instance, HIF-1α promotes the
expression of several glycolytic enzymes, such as hexokinase 1, phosphofructokinase,
and LDHA17,20. In contrast, HIF-2α has been demonstrated to regulate tumor initiation
2
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Figure 1: Post-translational regulation of HIFα subunits under normoxic and hypoxic conditions.
Left: Under normoxic (high O2 availability) conditions, the Hypoxia Inducible Factors (HIF)-1α and HIF-2α are
degraded. The prolyl hydroxylase (PHD) family of enzymes hydroxylate proline residues on the HIFα subunits,
which are recognized by the E3-ubiquitin ligase Von Hippel-Lindau (VHL). This reaction requires oxygen,
2-oxoglutarate, ascorbate, and iron (Fe2+) as cofactors. Once ubiquitinated, HIFα subunits are degrated
through the 26S proteasome. The Factor Inhibiting HIF (FIH) hydroxylates an asparagine residue on the
c-terminus of HIFα, which prevents HIFα from interacting with p300/CBP transcriptional co-factors. Reactive
oxygen species (ROS) can inhibit both PHD as well as FIH function. Right: Under hypoxic (low O2 availability)
conditions, HIFα are not hydroxylated, and can translocate to the nucleus where they bind to their constitutively expressed partner ARNT. p300/CBP serve as transcriptional co-factors. HIFα/ARNT recognize hypoxic
response elements (HRE) across the genome, and promote the transcription of several hundred different
genes involved in cellular processes that help the cell survive hypoxic stress (e.g. promote angiogenesis, alter
cellular metabolism), as well as genes that are often expressed in tumor cells (e.g. promote metastasis and
genes involved in stem cell identity). Although HIF-1α and HIF-2α both recognize the same HRE, they can
promote the expression of different genes.
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and proliferation through stem cell development, blood vessel remodeling, and
angiogenesis in multiple tumor contexts18,19. Whereas HIF-1α and HIF-2α are often protumorigenic, in specific cellular contexts they can also function to limit tumor growth. For
example, HIF-1α has been shown to act as a tumor suppressor in renal cell carcinoma21,
while HIF-2α inhibits lung tumor and hepatocellular carcinoma growth in vivo22,23.
The roles of the HIFs in STS are only beginning to be understood. In UPS and
fibrosarcoma, HIF-1α has been shown to drive metastasis through expression of
PLOD2, modifying the collagen milieu in the extracellular matrix to enhance migration
and metastasis24. However, the work presented here in Chapter 2 suggests HIF-2α has
a tumor suppressive function of HIF-1α in STS, since HIF-2α opposes the growth of
UPS, fibrosarcoma, and DD-LPS in vivo.
C. Epigenetic regulation of HIFα
In addition to the HIFα’s functions in cancer, the regulation of HIF expression is
also under active investigation. The HIFα subunits are thought to be primarily regulated
post-translationally through the prolyl-hydroxylases (PHD1, PHD2, PHD3) family of
enzymes and the factor inhibiting HIF (FIH). These enzymes hydroxylate specific proline
and asparagine residues on HIF-1α and HIF-2α, leading to their recognition by the E3ubiquitinating enzyme von-Hippel Lindau (VHL), and ultimately their degradation through
the 26S proteasome (Fig. 1). Beyond hydroxylation, it has demonstrated that
phosphorylation, acetylation20, and methylation25 of specific residues can affect HIF
activity and stability as well, although the outcome of these modifications can be HIFα
isoform dependent.

4

In the context of cancer, recent work has demonstrated that HIF expression can
be regulated at the transcriptional level through epigenetic mechanisms. Altered
epigenetics, or changes in gene expression not due to DNA sequence alteration26, has
been observed in many cancers, with deregulation of the epigenome proposed as an
important mechanism whereby tumors progress27. Epigenetic changes can occur at the
DNA level (e.g. DNA methylation to silence gene expression), as well as at the histone
level, where histones can be acetylated, methylated, and phosphorylated at specific
residues28. Depending on the specific histone modification, gene expression can be
increased (e.g. acetylation of specific histone lysines) or decreased (e.g. H3K9
methylation)28.
For the HIFs, epigenetic regulation of their expression is not completely
understood in the context of cancer. For example, it has been shown that HIF-2α
expression is repressed in differentiated kidney cells through DNA methylation by the
enzyme DNA methyltransferase 3a29. In renal cell carcinoma, where HIF-2α has been
demonstrated to be pro-tumorigenic30, DNA methyltransferase 3a inactivating mutations
commonly occur, causing de-repression of EPAS129. Interestingly, in work presented
here in chapter 2, several soft-tissue sarcomas repress EPAS1 expression through a
separate epigenetic mechanism, histone deacetylation, suggesting not only a context
specificity for epigenetic HIF expression or repression, but also for different epigenetic
mechanisms depending on the cancer type.
Part II. Interface between hypoxia, mTOR and calcium signaling
In addition to the HIF pathway, cells maintain their metabolic homeostasis
through independent, but closely linked molecular signaling networks. One major sensor
of nutrient availability is the mTOR (mammalian Target of Rapamycin) pathway. In brief,
5

the mTOR pathway integrates energy and nutrient sensing inputs by the cell, and
controls cellular growth and proliferation31. In mammals, there are two separate mTOR
catalytic units, called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
Both complexes share a catalytic mTOR subunit, mLST8, DEPTOR, and Tti1/Tel2
complex. mTORC1 also contains raptor and PRAS40, while mTORC2 has Rictor,
mSIn1, and protor1/2 proteins (Fig. 2). When mTORC1 is activated under energy or
nutrient replete conditions, it drives cell growth and protein synthesis through
phosphorylation of ribosomal S6 kinase 1 (S6K1), and the eukaryotic initiation factor 4E
binding protein (4E-BP1)31. In contrast, mTORC2 signaling, while much less understood,
appears insensitive to nutrient conditions but does respond to growth factors. One major
output of mTORC2 signaling is phosphorylation and activation of Akt at Ser47332, whose
activity can ultimately lead to mTORC1 activation (Fig. 2). It is not surprising that cancer
cells co-opt mTOR’s pro-growth pathway, either through modulating direct33 or indirect
(e.g. p5334 or PTEN35 loss; Akt35 or Ras36 activation) regulators of the pathway.
Numerous internal and external stresses can alter mTOR signaling in tumor cells,
including oxygen availability. One of the first connections identified between hypoxia and
mTOR demonstrated that andenosine monophosphate-activated protein kinase (AMPK)
phosphorylates TSC2 and inhibits mTORC1 in response to low energy or hypoxic
states37. Furthermore, mTORC1 was shown to promote glycolytic flux by promoting both
the transcription and translation of HIF-1α38,39. Loss of LKB1, the upstream kinase of
AMPK, increased HIF-1α accumulation through both increased reactive oxygen species
as well as mTORC1 activity40. However, HIF feeds back and inhibits the mTORC1
pathway in an AMPK independent manner, through transcribing regulation of
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Figure 2: The mTORC1 and mTORC2 pathway and its interaction with hypoxia
Key activators (green) and inhibitors (red) of the mTORC1/2 pathway are shown. A diverse array of
extracellular inputs, such as insulin, growth factors, and amino acids, can promote mTOR activity. These
signals lead to the inactivation of the TSC1/2 complex, the upstream inhibitor of mTORC1. This signals can
also activate mTORC2 through PIP3 and PDK1/AKT. For mTORC1, the main outputs are phosphorylated S6K1
and phosphorylated 4E-BP1 (bottom of the figure), which leads to increased ribosomal biogenesis and cap-dependent mRNA translation respectively. mTORC2 is associated with pro-survial activity, as well as modifying
the cytoskeleton and other metabolic adaptations. Rapamycin (light green box) inhibits mTORC1 activity, but in
certain contexts (e.g. prolonged exposure to rapamycin) can also inhibit mTORC2.
Through HIF-1α, hypoxia can inhibit mTORC1 through REDD1 or REDD2. Additionally, hypoxia can
lead to energy deficiency in a cell (e.g. high AMP/ATP ratio), which can inhibit mTORC1 through AMPK. Conversely, HIF-2α can enhance mTORC1 activity by promoting L-leucine amino acid import through the bidirectional amino acid transporter SLC7A5.
Calcium signaling can also activate mTORC1 signaling. Increased intracellular amino acids can
activate calmodulin (CaM), which can activate mTORC1 through hVps34. Also, higher intracellular calcium
levels can increase mTORC1 through activating CaMKII.
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DNA damage response 1 (REDD1)41. The isoform REDD2 is also hypoxically induced
and inhibits mTORC1, however its expression is restricted to certain tissues42,43.
Interestingly, HIF-2α affects mTORC1 in an independent manner from HIF-1α. In the
context of VHL-deficient mouse tissue and renal cell carcinoma lines, HIF-2α promotes
mTOR activity by driving expression of the amino acid transporter SLC7A544, which
functions as an antiporter by effluxing L-glutamine while importing L-leucine45. One
theory for this differential effect on mTORC1 could be due to the different kinetics of HIF1α versus HIF-2α stabilization. HIF-2α stabilization occurs in higher O2 over longer
periods of hypoxia, and cells may therefore require some basal activity of mTOR to
survive this longer-term stress. In contrast, HIF-1α is stabilized at lower O2
concentrations but degrades more rapidly than HIF-2α, and therefore inhibiting mTOR
short-term might be more beneficial to cell survival (Fig. 2).
In addition to the above-mentioned inputs that regulate mTOR signaling, calcium
availability and its downstream signaling also promote mTORC1. Amino acids are an
important activator of mTORC1 signaling46,47. Amino acids induce a rise of intracellular
calcium, and can trigger mTORC1 activation through calmodulin (CaM) and the lipid
kinase hVps3448. In addition, calcium can regulate mTORC1 through Ca2+/calmodulindependent protein kinase II (CaMKII). Phosphorylation of CaMKII leads to activation of
mTORC149,50, although the specific mechanism is not well-defined (Fig. 2).
In multiple different sarcoma subtypes, the PI3k-Akt-mTOR pathway has been
found to be abnormally activated51. Although different alterations of the pathway occur in
different sarcoma subtypes, such as inactivation of TSC2 in Kaposi sarcoma52 or
increased insulin-like growth factor receptor 1 levels in Ewing’s sarcoma53, overall the
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mTOR pathway has been found to be dysregulated in several types of sarcoma, and
may be an important therapeutic target for these diseases54.
Part III: Hypoxic regulation of autophagy

Autophagy is a cellular process whereby cells engulf and degrade proteins,
organelles, and cytoplasm to recycle them, providing substrates for energy production
and to sustain cellular metabolism55,56. Under a variety of stress conditions, including
nutrient or growth factor depravation, cytotoxic agents, and low oxygen availability57,
cells will activate autophagy. Depending on the cell context and type of cancer,
autophagy can either promote or inhibit tumor growth. In malignant cells, stress-induced
autophagy appears to be protective against adverse microenvironmental stresses and
cytotoxic therapies. However, in healthy tissues, autophagy mediates tumor suppressive
functions by preventing the accumulation of cellular stressors such as uncoupled
mitochondria, peroxisomes, and damaged endoplasmic reticulum58.
Several molecular sensors are responsible for detecting and translating these
wide varieties of homeostatic perturbations into a pro-autophagy signal. For example,
AMPK, which responds to increases in the AMP/ATP ratio in a cell, directly
phosphorylates ULK1, an autophagy initiation kinase59, as well as inhibiting mTOR37.
Misfolded proteins in the endoplasmic reticulum can activate autophagy through PERK
as well60. Another complex which activates autophagy is Vps34-p150-Beclin 1, where
Beclin 1’s autophagic function is inhibited by the anti-apoptotic protein Bcl-261 (Fig. 3)62.
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Figure 3: The autophagic pathway and its regulators
Autophagy (or macroautophagy) is a catabolic process in which double membrane vesicles called
autophagosomes sequester and degrade organelles, proteins, and other cytoplasmic constituents in response
to cell stress. The autophagic pathway consists of several steps, including nucleation and sequestration of a
phagophore, formation of a autophagosome and its fusion with a lysosome to form an autolysosome.
Initiation and nucleation of the autophagophore begins when several proteins, including ULK1 and
Beclin-1, which are inhibited by mTORC1 activity and BCL-2 respectively. BNIP3, a hypoxically induced
protein, displaces Beclin 1 from BCL-2. After nucleation, several ATG proteins are involved in the conjugation
of phosphatidylethanolamine (PE) to LC3, to form LC3-II. LC3-II is necessary for autophagic membrane expansion, recognition of autophagic cargo,and the fusion of lysosomes to autophagosomes. Another hypoxically
induced protein, BNIP3L, is involved in sequestering mitochondria to the autophagosome. p62 functions as an
autophagy cargo receptor, which is ultimately degraded when autolysosome forms. Once the autophagosome
has formed, it fuses with a lysosome to generate a autolysosome, leading to the degradation of the products
inside.
Several autophagic inhibitors exist, which can block autophagy at different steps along the pathway.
Shown here are bafilomycin A, chloroquine, and Lys05 block the step of autophagosome and lysosome fusion.
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Once the pro-autophagy signal is activated, an autophagosome is initiated, which is a
double membrane microvesicle. After being initiated, several other proteins elongate the
autophagosome, such as several proteins in the ATG family (e.g. ATG5, ATG7, ATG12,
ATG16), and LC3 conjugated to PE (LC3-II), which ultimately close the autophagosome
around the targets to be degraded. Once formed, the autophagosome can fuse to a
lysosome, creating an autolysosome, which ultimately degrades the contents held inside
(Fig. 3).
Multiple chemical inhibitors of autophagy exist that block different steps along the
autolysosome formation pathway63. One of the best-studied inhibitors is chloroquine (or
hydroxychloroquine), which was initially clinically approved as an anti-malarial treatment.
Chloroquine is a lysosomotropic agent, and it accumulates in acidic compartments such
as endosomes and lysosomes. There, it prevents acidification of the endosome, which in
turn inhibits lysosomal enzymes that require low pH to function. This effect inhibits fusion
and degradation of the lysosome with the autophagosome, thus preventing degradation
of the products inside. Bafilomycin A, another commonly used autophagy inhibitor,
inhibits autophagy at a similar step in the pathway64 (Fig. 3). Additionally, more specific
inhibitors of autophagy are under investigation (e.g. ATG7 inhibitors), but are still at the
preclinical stage of development63.
Although oxygen availability affects mTORC1, one of the main suppressors of
autophagy33 as described above, it also impacts autophagy regulators directly. For
example, BNIP3 and BNIP3L (NIX) are upregulated by HIF-1α65,66. Although these
proteins are implicated in apoptosis, it has also been shown that they disrupt Bcl2:Beclin 1 complex, freeing Beclin 1 to activate autophagy in cells (Fig. 3). BNIP3 and
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BNIP3L have also been shown to be important in autophagy-mediated mitochondrial
degradation, also termed mitophagy.
In the context of sarcoma, some preliminary studies of specific subtypes
demonstrate that autophagy plays an important role in cell survival. For instance, in a
screen of hypoxia-regulated genes in various soft tissue sarcomas from patients,
BNIP3L expression was found to be one of the most upregulated genes6, suggesting
autophagy may play an important role in these tumors’ ability to survive hypoxic stress.
In vitro studies of malignant peripheral nerve sheath tumors (MPNST) cells showed that
when treated with histone deacetylase inhibitors (HDACi), cells survived by activating
autophagy. Combining autophagy inhibition with HDACi promoted apoptosis in these
MPNST cells67. In gastrointestinal stromal tumors (GIST), autophagy inhibition
potentiated the effects of Imatinib, a tyrosine kinase inhibitor, and the combination of
both drugs increased cell death68. However, to date the effect of autophagy inhibition
has not been thoroughly analyzed in all subtypes of sarcoma, and clinical trials of
autophagy inhibitors are just starting to be performed in soft tissue sarcoma patients.
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CHAPTER 2: Epigenetic Re-expression of HIF-2α Opposes Aggressive Soft Tissue
Sarcoma Growth In Vitro and In Vivo
Sections of this chapter have been adapted from the following manuscript: “Epigenetic
re-expression of HIF-2α Suppresses Soft Tissue Sarcoma Growth” Nakazawa, M.S.,
Eisinger-Mathason, T.S., Sadri, N., Ochocki, J.D., Gade, T.P., Amin, R.K., Simon, M.C.,
Nature Communications (Under Review).

Abstract
In soft tissue sarcomas (STS), low intratumoral O2 (hypoxia) is a poor prognostic
indicator. HIF-1α mediates key transcriptional responses to hypoxia, and promotes STS
metastasis; however, the role of the related HIF-2α protein is unknown. Surprisingly, we
found that HIF-2α inhibits high-grade STS cell growth in vivo, as loss of HIF-2α
promoted sarcoma proliferation and increased calcium and mTORC1 signaling in
undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Most human
STS have reduced EPAS1 (the gene encoding HIF-2α) expression relative to normal
tissue. Many cancers, including STS, contain altered epigenetics, and our findings define
an epigenetic mechanism whereby EPAS1 is silenced during sarcoma progression. The
clinically approved HDAC inhibitor Vorinostat specifically increased HIF-2α, but not HIF1α, accumulation in multiple STS subtypes. Vorinostat inhibited STS tumor growth, an
effect ameliorated by HIF-2α deletion, implicating HIF-2α as a novel biomarker for
Vorinostat efficacy in STS.
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Introduction
Soft-tissue sarcomas (STS) are a diverse group of malignancies arising from
mesenchymal tissues, currently classified into approximately 50 distinct histological
subtypes1. Each year, 12,000 new cases are diagnosed in the United States, and
roughly 4,000 succumb to this disease69,70. While recent findings have defined molecular
mechanisms underlying sarcomagenesis and disease progression, these cancers
remain relatively understudied due to their varied clinical and pathological etiologies,
making effective treatment challenging2. Current therapeutic options for localized
disease include surgical resection, frequently in combination with radiation therapy and
chemotherapy. For metastatic or unresectable STS, cytotoxic chemotherapy remains the
primary approach; however, response rates are only 10 to 25%71,72. Therefore, it is
critical to identify novel therapeutics, as well as biomarkers to predict their efficacy, in
order to help improve patient outcomes.
Undifferentiated Pleomorphic Sarcoma (UPS), fibrosarcoma, and dedifferentiated liposarcoma (DD-LPS) are undifferentiated, high-grade sarcomas, which
collectively represent up to 40% of newly diagnosed sarcomas in adults3. UPS is among
the most aggressive STS subtypes in adults, with a five-year survival rate of only 24% in
patients with metastatic disease1,73. Although UPS comprises 15% of newly diagnosed
STS cases, its dedifferentiated phenotype suggests that it may represent a
morphological end-point for many other sarcomas3,74. Further characterization may
therefore provide broader insights into other aggressive STS subtypes.
One prominent feature of STS, including UPS, are severely hypoxic regions, a
phenotype associated with lower overall survival rates5,75,76. Cellular adaptation to
hypoxic stress requires coordinated changes in gene expression, many of which are
14

mediated by Hypoxia-Inducible Factor (HIF)-1α and HIF-2α12,77,78. Although HIF-1α and
HIF-2α are stabilized under hypoxic conditions, extensive data indicate that many
important HIF targets are controlled specifically by one isoform or the other17,18,20,21.
Additionally, the impact of HIF-α isoform stabilization is context-dependent, as they have
been demonstrated to promote or suppress tumor growth in different cancers21-23.
Several HIF inhibitors have been developed for clinical intervention, and while certain
compounds demonstrate isoform-specific inhibition79, many affect both HIF-1α and HIF2α equally80,81. Thus, the role of both HIF-α subunits in specific tumor contexts must be
characterized before using either pan or isoform-specific HIF-α drugs.
Whereas HIF-1α has recently been shown to promote metastasis in UPS and
fibrosarcoma24, the role of HIF-2α in STS has not been established. Using a genetically
engineered UPS mouse model that faithfully recapitulates human disease82,83, as well as
fibrosarcoma and liposarcoma xenografts, we found that HIF-2α expression surprisingly
suppresses tumorigenesis. Loss of HIF-2α (encoded by the EPAS1 gene) increased
sarcoma tumor cell proliferation. Additionally, RNA-seq analysis indicated that
Anoctamin-1 (ANO1, DOG1, TMEM16A)84, encoding a calcium-activated chloride
channel, was expressed at elevated levels in HIF-2α deficient autochthnous UPS tumors
relative to controls. In turn, ANO1 overexpression coincided with elevated CAMKII and
mTORC1 signaling in these tumors. mTORC1 senses nutrient availability, and regulates
cellular growth, biosynthetic activity, and ribosomal biogenesis85; as such, dysregulation
of this pathway occurs in a variety of cancer types, including sarcomas86. Decreased
EPAS1 mRNA expression (with no copy number variation) was detected in the majority
of STS patient samples analyzed, including UPS, fibrosarcoma, and liposarcoma. These
data suggest that EPAS1 expression is suppressed by epigenetic mechanisms in
15

multiple sarcoma subtypes. Altered epigenetics have been observed in many cancers,
with dysregulation of the epigenome proposed as an important mechanism whereby
tumors progress27. Of note, treatment with the chromatin modifying agent
suberanilohydroxamic acid (SAHA, Vorinostat), a clinically approved histone deacetylase
inhibitor (HDACi)87, significantly increased HIF-2α expression in several STS, and
inhibited growth in a HIF-2α dependent manner.
Results
HIF-2α suppresses tumor growth in UPS

To address the role of HIF-2α in soft-tissue sarcomas, we crossed the previously
described autochthonous “KP” (LSL-KrasG12D/+; Trp53fl/fl) UPS mouse strain83 with
Epas1fl/fl mice88 to generate “KPH2” (LSL-KrasG12D/+; Trp53fl/fl; Epas1fl/fl) animals. Hind
limb UPS tumors are generated by injection of adenovirus expressing Cre recombinase
(Ad-Cre) into the gastrocnemius muscle. Of note, KPH2 mice formed UPS lesions at a
significantly elevated rate compared to KP control animals, with 50% of KP and KPH2
strains forming tumors 56 and 47 days, respectively, after Ad-Cre injection (Fig. 4a).
KPH2 tumors were larger than KP controls, with significantly increased mass at 7 weeks
post-Ad-Cre injection (Fig. 4b) PCR analysis confirmed efficient Epas1 deletion in KPH2
tumors (Fig. 4c). Both KP and KPH2 samples displayed a similar heterogeneous,
multinucleated appearance consistent with UPS, and local muscle invasion was also
observed, albeit more extensively in the KPH2 than KP tumors (Fig. 4d). In agreement
with prior reports24, KP and KPH2 tumors exhibit areas of localized hypoxia, as
demonstrated by Hypoxyprobe staining (Fig. 4e). KPH2 tumors were also more
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Figure 4: Loss of HIF-2a promotes UPS tumor growth in vivo. a. Tumor latency of LSL-KrasG12D/+;Trp53fl/fl
(KP, n = 16) and LSL-KrasG12D/+;Trp53fl/fl;Epas1fl/fl (KPH2, n = 19) mice, shown as days post-injection of Ad-Cre
virus. b. Left: A cohort of KP (n = 7) and KPH2 (n = 9) mice were sacrificed 7 weeks post-Ad-cre virus injection. Representative images of the hind limb where Ad-cre was injected in each cohort are shown. Right:
Weight of KP and KPH2 tumors at 7 weeks post-Ad-cre injection (grams). * = P < 0.05. c. Genotyping of KPH2
tumors shows efficient Epas1 recombination. Controls include DNA derived from a KP tail (WT), muscle from a
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proliferative than KP, as demonstrated by BrdU uptake (Fig. 5a), while apoptotic rates
were unchanged based on cleaved Caspase-3 levels (Fig. 5b). To assess if HIF-2α loss
affected the migration or metastatic potential of UPS, we first performed in vitro Boyden
chamber migration experiments under normoxic and hypoxic conditions (1%) using
tumor cells isolated from KP and KPH2 mice. Under hypoxic conditions, a similar
number of KP and KPH2 cells migrated (Fig. 5c). We next performed an in vivo
metastasis assay as previously described24, with KP, KPH2, and KIA (as a positive
control) subcutaneous allografts. While 6/10 KIA mice showed metastasis in their lungs
(indicated by arrowhead), mice with KP (0/10) or KPH2 (0/10) tumors did not have lung
metastasis at the time of sacrifice (Fig 5d – 5e).
Although HIF-1α and HIF-2α have unique transcriptional targets, they also
regulate common genes in a coordinate or even opposing manner17,20,21. To rule out the
possibility that the effects of HIF-2α deficiency in vivo were due to compensatory HIF-1α
activity, we deleted Arnt, the obligate binding partner of both HIF-1α and HIF-2α.
Compared to KP mice, LSL-KrasG12D/+; Trp53fl/fl; Arntfl/fl (KPA) animals generated larger
lesions, phenocopying KPH2 tumor characteristics. Seven weeks following Ad-Cre
injection, KPA tumors had significantly greater mass (Fig. 6a), indicating that the effects
of HIF-2α deletion are not due to HIF-1α-mediated compensation. Together, these data
indicate that HIF-2α suppresses UPS tumorigenesis, in contrast to HIF-1α which has no
effect on primary tumor growth in this model24.
Loss of HIF-2α promotes liposarcoma and fibrosarcoma tumor growth in vivo
To determine whether HIF-2α expression was decreased in other STS subtypes,
we first queried publicly available microarrays of human STS using Oncomine. Analysis
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of a dataset originally published by Barretina et. al.89 showed that EPAS1 mRNA
expression was lower in fibrosarcoma, leiomyosarcoma, liposarcoma, and UPS
(previously named Malignant Fibrous Histiocytoma) patient samples compared to normal
adipose tissue (Fig. 7a). Additionally, liposarcoma and UPS tumors demonstrated
decreased immunostaining for HIF-2α compared to normal artery and skeletal muscle
tissue (Fig. 7b). In a separate dataset90, decreased EPAS1 mRNA expression correlated
with worse survival in liposarcoma patients (Fig. 7c). Of note, EPAS1 levels were
significantly lower in more aggressive liposarcoma subtypes, such as dedifferentiated
and pleomorphic liposarcoma (Fig. 7d - 7e), and in this dataset, the bottom 50% EPAS1
expressing cohort have a higher risk of death (relative risk of 6.67) compared to the top
50% EPAS1 expressing cohort. Collectively, these analyses indicate EPAS1 expression
is decreased in multiple STS subtypes, and lower EPAS1 levels correlate with poorer
prognosis in a set of liposarcoma patients.
To test the functional effects of HIF-2α suppression in different STS subtypes, we
inhibited HIF-2α using two independent shRNAs in LPS246 liposarcoma cells, which
resulted in increased xenograft volume growth and mass (Fig. 8a – 8c). Furthermore,
HIF-2α depletion promoted growth of HT-1080 fibrosarcoma tumor xenografts in vivo
(Fig. 9a – 9c). Importantly, HIF-1α ablation did not affect tumor growth (Fig. 9c),
consistent with previous reports24. These results demonstrate that inhibition of HIF-2α in
vivo accelerates growth of multiple soft-tissue sarcomas, including UPS, fibrosarcoma,
and liposarcoma.
Loss of HIF-2α Increases mTORC1 Signaling in Soft Tissue Sarcomas
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To define mechanism(s) whereby HIF-2α opposes sarcomagenesis using an
unbiased approach, we performed RNA-seq analysis of KP (n=3) and KPH2 (n=4)
tumors. By principle component analysis, KP and KPH2 tumors segregated into distinct
populations (Fig. 10a). Gene set enrichment analysis of differentially expressed genes
revealed a strong enrichment for those regulating RNA Polymerase I promoter opening
and transcription in KPH2 compared to KP samples (Fig. 10b – 10c), suggesting
increased ribosome biogenesis in the KPH2 tumors. As c-MYC and mTORC1 signaling
promote proliferation and ribosome biogenesis in cancers85,91, we assessed whether
either pathway was more active in KPH2 tumors compared to KP controls. KPH2 tumors
displayed increased c-MYC protein levels, but modest increases in the expression of
several canonical c-MYC target genes (Myc, Ccnd1, Ccdn2, Mcm5, Cdkn1a) (Fig. 11a)
were observed (for more discussion on this matter, see below). Additionally, Ingenuity
Pathway Analysis (IPA) did not predict c-MYC activation in KPH2 tumors (data not
shown). In contrast, IPA predicted increased mTOR activity based on differentially
expressed mTOR targets between KP and KPH2 tumors (Fig. 11b). The canonical
mTORC2 target, phosphorylated AKT at serine 473, was not significantly different
between KP and KPH2 tumors (Fig. 11c)32. However, using a Fischer’s exact test, we
determined that KPH2 tumors had a statistically significant mTORC1 target gene
signature, for targets predicted to be both elevated (p = 0.014) and suppressed (p =
0.010) by mTORC192. Canonical mTORC1 signaling outputs, phosphorylated 4E-BP1
and S6K193, were also assessed in KP and KPH2 tumors, and elevated 4E-BP1
phosphorylation was observed in KPH2 tumors compared to KP (Fig. 11c). We
perceived variable increases in S6K1 phosphorylation in whole KP and KPH2 UPS
lysates, indicating that mTORC1 activity may vary in tumor subdomains. Therefore, we
examined phosphorylated S6 staining in tumor parenchyma by IHC, and noted
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significantly expanded areas of phosphorylated S6 in KPH2 (n = 5) compared to KP (n =
5) sections (Fig. 11d). Phosphorylated 4E-BP1 levels were elevated in KPH2 tumorderived cells as compared to KP tumor-derived cells, with the expected increase in
unphosphorylated 4E-BP1 under hypoxic growth conditions (Fig. 11e – 11f). Consistent
with this finding, proliferation was also increased in KPH2 cells (Fig. 11g). Similar
increases in phosphorylated 4E-BP1, S6K1 and S6 were apparent in HIF-2α knockdown
LPS246 xenografts (Fig. 12a – 12b). Although some heterogeneity exists in tumors
expressing or lacking HIF-2α, taken together, these data indicate that mTORC1 activity
is increased in HIF-2α deficient sarcomas.
To elucidate the mechanisms whereby HIF-2α alters mTORC1 activity in UPS,
we examined the top differentially expressed genes base on RNA-seq data. Several
targets identified were related to skeletal muscle and extracellular matrix consistent (e.g.
Lama5, Col18a1, Dmp1), with KPH2 showing more local invasion into the adjacent
skeletal musculature (Fig 4d, 13a). However, Ano1 (encoding TMEM16A, Anoctamin 1,
DOG1) transcripts were significantly increased in KPH2 tumors relative to controls (Fig.
13b). ANO1, a protein encoding a calcium activated chloride channel84, is
overexpressed in a variety of cancers, including gastrointestinal stromal tumors (GIST),
breast cancer, and head and neck cancers94-96. KPH2 tumors also exhibited elevated
ANO1 protein levels compared to KP tumors (Fig 13c), although the available antibody
exhibited relatively weak immunoreactivity with both KP and KPH2 tumor lysates.
ANO1 has previously been reported to promote both EGFR and CaMKIIα
signaling in breast cancer cell lines96. While we failed to observe a consistent pattern of
increased EGFR phosphorylation in KPH2 tumors (Fig. 13c), these tumors expressed
higher levels of phosphorylated CaMKIIα (Fig. 13c). These data are consistent with IPA
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Figure 13: Ano1 and calcium signaling is enhanced in HIF-2α deficient UPS tumors. a Ten most differentially expressed genes from RNA-seq of KP and KPH2 tumors. Fold changes indicated are expression changes in KPH2 tumors compared to KP tumors. b. qRT-PCR Validation of Ano1 mRNA expression in KP (n = 4)
and KPH2 (n = 3) tumors used for RNA-seq. * = P < 0.05. c. Immunoblot of ANO1 and downstream targets
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analyses, which predicted increased calcium signaling in KPH2 tumors (Fig. 13d). Since
intracellular calcium and CaMKIIα have been shown to enhance mTORC1 signaling49,50,
we hypothesized that increased mTORC1 activity in KPH2 tumors was mediated through
ANO1 and CAMKII signaling. To test this, we serum starved KP and KPH2 tumor
derived cells for 24 hours, and then treated with replete media plus DMSO or CaCCinhA01, a small molecule inhibitor of ANO1 activity96. KPH2 cells maintained higher levels
of ANO1 compared to KP in vitro (Fig. 14a), although this phenotype is more striking in
tumors, likely due to the normoxic cell culture conditions. As expected, CaCCinh-A01
treatment reduced phosphorylated CaMKII levels more effectively in KPH2 compared to
KP cells (Fig. 14b). Moreover, CaCCinh-A01 diminished mTORC1 activation (Fig. 14b),
consistent with our findings that ANO1 is more highly expressed in KPH2 cells. In
addition, CaCCinh-A01 treatment decreased cell proliferation more potently in KPH2
than KP cells after 3 days of treatment (Fig. 14c). To determine if ANO1 inhibition
diminished HIF-2α deficient sarcoma growth in vivo, Ano1 targeted shRNA were
introduced in KP and KPH2-derived UPS cells (Fig. 14d - 14e), to generate allografts.
Similar to our in vitro data, inhibition of ANO1 significantly reduced tumor growth in
KPH2 but not KP allografts (Fig. 14f – 14g). Collectively, these data suggest that loss of
HIF-2α increases ANO1 accumulation, activating CaMKII and mTORC1 signaling in UPS
tumors and enhancing their growth (see below for further discussion).
HDAC inhibition increases EPAS1 expression in UPS
Having determined that HIF-2α has a tumor suppressive role in UPS and other
STS, we examined possible mechanisms whereby HIF-2α is silenced in these lesions.
Initially, we analyzed Epas1 expression over time in the KP tumor model. One cohort of
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animals was euthanized 7 weeks post Ad-cre injection (“KP early”, n = 7), and another at
8.5 weeks post Ad-cre injection (“KP late”, n = 9). Epas1 mRNA levels in the KP late
cohort were significantly diminished compared to KP early, with Epas1 mRNA of mouse
skeletal muscle shown as a comparison (Fig. 15a). Therefore, we concluded that Epas1
expression is lost progressively over the course of sarcomagenesis. Analysis of TCGA
sarcoma patient samples revealed that 25% of all human sarcomas have lost at least
one copy of EPAS1, while 67% have diploid copy number at this region (Fig. 15b). As
EPAS1 mRNA levels are consistently diminished in several STS subtypes (Fig. 7a), we
hypothesized that EPAS1 is epigenetically silenced in a significant fraction. Using a
publically available dataset of human sarcoma cell lines treated with various cancer
therapeutics, we identified a significant correlation between EPAS1 mRNA abundance
and sensitivity to the histone deacetylase inhibitor (HDACi) Vorinostat, also known as
suberanilohydroxamic acid (SAHA) (Fig. 15c - 5d)97. In contrast, no such correlation
existed between HIF1A expression and SAHA sensitivity in the same cell lines (Fig.
15e). We also analyzed DNA methylation along the EPAS1 locus in the TCGA sarcoma
dataset, and found no consistent methylation changes in the samples (Table 1).
Together, these results suggest that HDACs specifically suppress EPAS1 in sarcoma,
and that re-expressing EPAS1 could be a mechanism underlying HDACi’s inhibition of
sarcoma growth.
To test whether HDACi could activate EPAS1 expression in sarcoma, two
independent mouse UPS cell lines, derived from KP tumors (KP230 and KP250), were
treated with multiple SAHA concentrations (500 nM - 2 µM) in vitro. SAHA exposure
increased Epas1 mRNA levels (Fig. 16a), an effect also observed in HT-1080 cells (Fig.
16b). Importantly, at the highest dose tested (2 µM), SAHA treatment had no effect on
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Table 1: DNA methylation across the EPAS1 locus from the Cancer Genome Atlas (TCGA)
sarcoma samples. Primary solid tumors (n = 242), recurrent solid tumors (n = 2), metastatic (n =
1), and normal solid tissue (n = 4) were analyzed, and the mean Beta-values for each group
shown. P-values comparing tumor tissue versus normal tissue Beta-values were calculated for
each probe using DEseq.
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HIF1A mRNA in UPS or HT-1080 cell lines (Fig. 16b – 16c). Consistent with these
findings, 2µM SAHA also increased HIF-2α protein levels in both KP230 and KP250
cells, while HIF-1α protein was unchanged (Fig. 16d). SAHA treatment also resulted in
elevated mRNA levels of Serpine1, a HIF-2α target98, at all concentrations tested (Fig.
16e). Chromatin immunoprecipitation (ChIP) was performed to verify that SAHA
exposure increased the abundance of acetylated histones at the Epas1 locus. Using
available ChIP-seq data from the UCSC genome browser, primers targeting the region
500 bp upstream of the Epas1 transcription start site (TSS) were designed. ChIPseq/RNA seq analyses of EPAS1 expressing tissues indicated this region is rich in
histone acetylation. Treatment with 2µM SAHA increased levels of acetylated histone H3
(H3Ac) near the Epas1 TSS compared to DMSO control under normoxic (21% O2) and
hypoxic (0.5% O2) conditions (Fig. 16f). Conversely, no increases in H3Ac at 500 bp
upstream of the Hif1a TSS were detected.
To rule out off-target effects of SAHA on EPAS1, we treated KP230, KP250, and
HT-1080 cells with an independent class I/II HDACi, Trichostatin A (Fig. 17a).
Trichostatin A increased Epas1 and Serpine1 mRNA levels, but had no effect on Hif1a
mRNA expression. However, treatment with nicotinamide, a class III HDACs/sirtuins
inhibitor99, did not change Epas1 or Hif1a mRNA levels in the same cell lines (Fig. 17b).
We also investigated whether altering DNA methylation would affect EPAS1 expression,
given that DNA methylation regulates EPAS1 in renal cell carcinoma29. However,
treatment with 5-azacytidine, a DNA methyltransferase inhibitor100, and 3Deazaneplanocin A (DZNEP), a EZH2 histone methyltransferase inhibitor, failed to
significantly increase Epas1 mRNA levels in UPS cell lines (Fig. 17c). In aggregate,
these results indicate that HIF-2α expression is lost during UPS disease progression,
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and epigenetic therapeutics like SAHA specifically elevate HIF-2α, but not HIF-1α,
levels.
SAHA inhibits UPS allograft growth, dependent on HIF-2α re-expression
Findings described above suggest that SAHA treatment may suppress sarcoma
cell proliferation and tumor growth. We first tested this hypothesis by investigating
SAHA’s ability to inhibit UPS, HT-1080, and LPS246 sarcoma cell proliferation in vitro.
Of note, SAHA treatment significantly decreased cell growth under both normoxia and
hypoxia (1% O2) (Fig. 18a – 18c).
Next, we evaluated SAHA’s therapeutic efficacy against UPS allografts in vivo,
and found that SAHA administration (50 mg/kg/day) significantly reduced tumor growth
(Fig. 18d), and final tumor weights (Fig. 18e). Importantly, no obvious adverse effects of
treatment were observed, and the mice maintained weight similar to DMSO treated
controls (Fig. 18f). Surprisingly, Epas1 mRNA levels were only slightly elevated in the
SAHA treated tumors compared to controls, although there was no change in Hif1a
levels, as expected (Fig. 19a). We suspected that KP tumor cells developed resistance
to SAHA, and its effect on Epas1 re-expression, over the extended course of the
experiment (8 days). Consistent with this hypothesis, tumors from UPS bearing mice
treated with SAHA for only 4 days displayed significantly increased Epas1 mRNA levels
(Fig. 19b).
As SAHA can affect multiple cellular targets and processes101, we assessed the
specific role of HIF-2α in SAHA-mediated anti-tumor effects. Two independent shRNAs,
one producing a partial inhibition (H2α shRNA 1), and a second more effective shRNA
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Relative tumor size increase of KP250 allografts treated with DMSO control (n = 4) or SAHA (50 mg/kg/day, n
= 4). Right: Epas1 and Hif1a mRNA expression from KP250 allografts after 4 days of DMSO or SAHA treatment. * = P < 0.05.
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(H2α shRNA 2), were used to deplete HIF-2α in KP250 cells (Fig. 20a). Both HIF-2α
shRNAs inhibited SAHA-induced Epas1 and Serpine1 mRNA re-expression in UPS cells
(Fig. 20b). Mice bearing in vivo UPS allografts expressing control or HIF-2α shRNAs
were then treated with DMSO or SAHA (50 mg/kg/day) once tumors had reached 100
mm3 (10 days post-implantation). SAHA significantly slowed the growth of control
tumors, while HIF-2α inhibition abrogated this effect in a dose-dependent manner (Fig.
20a). Conversely, overexpression of HIF-2α in HT-1080 fibrosarcoma cells inhibited cell
proliferation in vitro under hypoxic conditions (Fig. 21a – 21b). When treated with SAHA,
we observed a further increase of HIF-2α mRNA and protein expression in empty vector
and HIF-2α overexpression cells, and a further decrease in cell proliferation likely due to
increased expression of the endogenous HIF-2α mRNA (Fig. 21c).
The standard chemotherapeutic approach for unresectable STS is doxorubicin71.
In order to demonstrate that SAHA treatment could be safely and effectively
incorporated into the clinical setting, we investigated the efficacy of combining
doxorubicin and SAHA. Although combination therapy reduced UPS allograft growth in
vivo compared to DMSO or doxorubicin alone (Fig. 22a), this inhibition was similar to
SAHA treatment alone (Fig 20a). Moreover, HIF-2α inhibition in these allografts fully
abrogated this effect. (Fig. 22b – 22c). Collectively, these data strongly suggest that
SAHA limits UPS proliferation in vitro and in vivo, in a HIF-2α dependent manner.
HIF-2α expression is required for SAHA’s efficacy in an autochthonous UPS model
We next evaluated the efficacy of SAHA in an autochthonous STS tumor model,
using KP mice. After initiating tumors with Ad-Cre injection, we performed bi-weekly CT
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scans of the animals’ lower limbs. When tumors reached 50-100 mm3, animals were
treated with DMSO or SAHA (50 mg/kg) daily (Fig. 23a). SAHA decreased relative tumor
growth over time, compared to controls (Fig. 23b), resulting in significantly reduced
relative tumor size by day 10. (Fig. 23c). Total animal weight did not change due to
SAHA treatment (Fig. 23d). Importantly, HIF-2α protein levels increased in SAHAtreated tumors compared to controls (Fig. 23e). SAHA also decreased KP tumor cell
proliferation, as indicated by reduced Ki67 staining (Fig. 23f) with no concomitant
change in apoptosis, as shown by cleaved Caspase-3 immunohistochemical staining
(Fig. 23g). Importantly, SAHA’s effects on tumor growth (Fig. 24a – 24b) and
proliferation (Fig. 24c – 24d) were completely abrogated in KPH2 tumors, underscoring
the importance of HIF-2α in SAHA-mediated anti-tumor effects.
Discussion
Current chemotherapeutic approaches for the treatment of unresectable and
metastatic soft-tissue sarcomas have low response rates71,72. One major obstacle to
developing better treatment regimens has been the myriad of unique subtypes with
distinct genetic alterations2,70, coupled with the relatively low incidence of these
malignancies. Until recently, clinical trials often combine patients with diverse STS
histologic subtypes, which are induced by heterogeneous genetic alterations potentially
from multiple cells of origin, into a single study. Our growing understanding of context
specificity in tumors, particularly in sarcomas, has shown that this approach has many
drawbacks. Newer targeted therapies are increasingly being investigated, not only in a
sub-type specific manner, but also based on the molecular underpinning of the
tumors102. It will be very beneficial to identify therapeutic biomarkers that span multiple
subtypes and determine treatment strategies based on gene expression changes that
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are linked to drug sensitivity. Identification of biomarkers that predict drug response
should allow clinicians to better select patient populations most likely to respond to
treatment2. Although these biomarkers are scarce in STS, we report here that HIF-2α
expression levels may be particularly effective for this purpose.
Clinical data have identified intratumoral hypoxia and HIF-1α as one of the most
important prognostic factors in metastatic potential of STS103,104. Consistent with this
finding, we have shown previously that HIF-1α enhances tumor metastasis through
modifications of the collagen network in UPS and fibrosarcoma24. Conversely, we
demonstrate here that HIF-2α expression opposes UPS, fibrosarcoma, and liposarcoma
growth in vivo, decreasing tumor cell proliferation and inhibiting mTORC1 activity.
Although tumors exhibit significant heterogeneity in our in vivo models, both within a
given sample and between samples, we saw significant enrichment of mTORC1
activation. Importantly, further work is necessary to determine if this mechanism is
shared in other STS subtypes not examined here. It is noteworthy that low HIF-2α
expression is correlated with lower overall survival rate in a cohort of liposarcoma
patients90. Additionally, loss of HIF-2α did not alter metastatic potential in UPS in vitro or
in vivo. Although mTORC2 signaling has been shown to promote HIF-2α accumulation in
cancers like renal cell carcinoma105, our results suggest that HIF-2α inhibits mTORC1
signaling in at least the high-grade STS subtypes examined. This context dependency of
HIFs and mTOR signaling in cancer warrants further study. For UPS tumors, loss of HIF2α increases ANO1, promoting CaMKII and mTORC1 activity (Fig. 25a). Interestingly, a
previous study demonstrated that HIF-1α inhibition increased ANO1 mRNA expression
in renal cysts106, yet we are the first to connect HIF-2α loss with increased ANO1 in UPS.
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However, HIF-2α may also inhibit sarcoma growth in an ANO1 and mTORC1independent fashion (Fig 25a). Given the multitude of targets and biological processes
HIF-2α controls, the mechanism whereby HIF-2α inhibition increases ANO1 levels
remains to be elucidated. Importantly, ChIP-seq data assembled in the UCSC genome
browser show Myc/Max binding near the promoter region of ANO1 in breast and
leukemia cells. Thus, one possible explanation for our findings is that Myc, whose levels
are elevated in KPH2 tumors (Fig 11a), binds to the ANO1 promoter and increases
ANO1 expression. c-MYC stimulation (or repression) of individual target genes can be
modest107, and additional factors are required to regulate many c-MYC driven targets91.
While the canonical c-MYC target genes we examined were slightly elevated in KPH2
tumors, Ano1 expression was significantly increased, suggesting other input(s) are likely
influencing its transcription. Clarifying the specific mechanism of HIF-2α mediated ANO1
regulation will be an important topic of future studies.
Observations that HIF-1α and HIF-2α can play different and often opposing roles
in various malignancies is important as HIF inhibitors are systematically being developed
as cancer therapies20. For example, HIF-2α in clear-cell renal cell carcinoma promotes
tumorigenesis21,30, whereas it suppresses tumorigenesis in hepatocellular carcinoma and
non-small cell lung adenocarcinoma22,23. Although HIF-α subunit specific inhibitors are
currently under investigation79, pan-HIFα inhibitors are also being assessed80,81. Our
results with ARNT knockout KP mice caution against the use of pan-HIFα inhibitors for
the treatment of STS and potentially for other tumors as well.
Given that HIF-2α expression opposes STS tumorigenesis, we sought a class of
compounds that could induce re-expression of HIF-2α in sarcoma cells, and found that
the FDA-approved histone deacetylase inhibitor (HDACi) SAHA (Vorinostat) reactivates
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EPAS1 expression in STS cells, inhibiting sarcoma progression (Fig 25a). HDACi have
been assessed in vitro and in vivo pre-clinically for the treatment of a variety of
malignancies, including specific sarcoma subtypes such as malignant peripheral nerve
sheath tumors67 and synovial sarcoma, with some early success108-110. Clinical trials
testing chemotherapy with HDACi in STS are still ongoing, as well as newer generations
of HDACi, such as abexinostat, with potentially improved anti-tumor effects and
pharmokinetics111. To our knowledge this study is the first to show HDACi treatment
reduces growth of autochthonous UPS tumors in vivo, and demonstrate that HIF-2α reexpression is required for SAHA’s anti-proliferative effects in the context of UPS.
Importantly, combination of standard doxorubicin, a first-line chemotherapeutic
against STS, with SAHA could be a suitable treatment strategy that has exciting clinical
potential. These results suggest that HDACi therapies will be most effective against
sarcomas that have epigenetically suppressed HIF-2α expression, and not genomic
deletion of the locus. HIF-2α may therefore serve as an important biomarker for
clinicians designing future clinical trials with HDAC inhibitors in sarcoma patients.
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Chapter 3: Autophagy Inhibition as a Therapeutic Strategy Against Soft Tissue
Sarcomas
Sections of this chapter have been adapted from the following manuscript: “Autophagic Inhibition
as a Therapeutic Strategy For Soft Tissue Sarcomas” Nakazawa, M.S., Amin, R.K., Azzam, A,
Campbell, S.L., McLellan, R., Simon, M.C. Autophagy (In Preparation).

Abstract
Autophagy is a lysosomal dependent process that helps cells survive under
stressful growth conditions. Soft tissue sarcomas (STS) frequently contain areas of
hypoxia (low O2), which correlates with worse survival in patients. Hypoxia can promote
autophagy in cancers through stabilization and activation of the Hypoxia Inducible
Factors (HIFs). However, the role of hypoxia and autophagy in STS survival remains to
be fully elucidated. In this study, we demonstrate that hypoxic and ischemic-like stress
increases autophagic flux in fibrosarcoma and undifferentiated pleomorphic sarcoma
(UPS) cells, rendering them more sensitive to autophagy inhibition. In addition, loss of
HIF-1α in STS sensitized cells to the autophagic inhibitor chloroquine. Pharmacologic
inhibition of autophagy with chloroquine as a monotherapeutic significantly reduced
growth of UPS tumors in vivo. Furthermore, mice treated with Lys05, a more potent
autophagy inhibitor than chloroquine, significantly slowed tumor growth in vivo in
fibrosarcoma and UPS tumors.
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Introduction:
Autophagy is a cellular process whereby proteins, organelles, and cytoplasm are
engulfed in autophagic vesicles and subsequently degraded112, in order to provide
substrates to maintain energy production and sustain cellular metabolism55,56. Under
stress conditions, activation of autophagy can promote cell survival. In particular,
autophagy in transformed tumor cells promotes survival by reducing metabolic and
cytotoxic therapy induced stress113,114.
As solid tumors outgrow their native blood supply, they develop areas of hypoxia,
or low O2 conditions12, which promotes autophagy33. One of the main sensors of hypoxia
is a set of transcription factors called the hypoxia inducible factors (HIFs), which
modulate gene expression under hypoxic stress12. Under hypoxia, the oxygen labile HIF1α and HIF-2α subunits heterodimerize with the constitutively stable HIF-1β subunit
(also known as ARNT), and bind to HIF-response elements (HREs) on the genome to
promote gene expression12,13. Although oxygen availability affects mTORC1, one of the
main suppressors of autophagy33, it also impacts autophagy regulators directly. For
example, HIF-1α upregulates BNIP3 and BNIP3L expression, which can induce
autophagy and mitophagy (mitochondrial clearance) respectively65,66.
Soft tissue sarcomas (STS) are a rare group of malignancies that arise from
mesenchymal tissue1, and frequently contain areas of significant hypoxia4,103. Hypoxia in
STS has been correlated with worse outcomes5, and in high-grade fibrosarcoma and
undifferentiated pleomorphic sarcoma (UPS) subtypes, HIF-1α has been demonstrated
to promote metastasis24. Furthermore, hypoxia has also been associated with resistance
to therapy in solid tumor types7. In a screen of hypoxically-regulated genes in STS from
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patients, BNIP3L expression was found to be one of the most upregulated genes,
suggesting that autophagy plays a role in these tumors’ survival under hypoxia6. Indeed,
preclinical studies have shown that autophagy can promote cell survival of certain STS
subtypes, such as malignant peripheral nerve sheath tumors (MPNST)67 and
gastrointestinal stromal tumors68. However, the role of autophagy and hypoxia in
fibrosarcoma and UPS remains unclear. We demonstrate here that in both fibrosarcoma
and UPS cells, pharmacologic inhibition of autophagy with chloroquine or bafilomycin A
suppresses growth, and under hypoxic and ischemic-like conditions, they show
enhanced sensitivity to these therapeutics. Loss of HIF-1α in STS further sensitizes cells
to autophagic inhibition in vitro. In vivo, chloroquine administration reduced tumor burden
in fibrosarcoma xenografts and UPS allografts. Furthermore, Lys05, a bivalent
aminoquinoline autophagy inhibitor that is more potent than chloroquine115, reduced
tumor growth in vivo at a more permissive drug delivery schedule than chloroquine.
These data suggest that inhibiting autophagy may be a relevant target in fibrosarcoma
and UPS patients, and warrant further study.

Results:
Increased Sensitivity to Autophagy Inhibition Under Stress Conditions in Fibrosarcoma
and UPS cells

Initially, we assessed whether autophagy was important for STS cell survival
under stress conditions. Using chloroquine (CLQ), a well-established inhibitor of
autophagy63, we assessed whether HT-1080 fibrosarcoma cells and KIA and KP
undifferentiated pleomorphic sarcoma cells24,83 were sensitive to autophagy inhibition.
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While all three cell lines had varying IC50 when treated with chloroquine under replete
and normoxic conditions, hypoxic (1% O2) and low serum and glucose (1% FBS, 1 mM
glucose) conditions increased their sensitivity to chloroquine (Fig. 26a – 26c).
Combining these stresses to mimic ischemia, these STS cells showed even greater
sensitivity to autophagy inhibition (Fig. 26d).
We next assessed whether chloroquine treatment would affect cell proliferation
under similar growth conditions. HT-1080 cells under replete and normoxic conditions
showed decreased cell growth only under high doses of chloroquine (100 µM) (Fig.
27a). However, under either 1% O2, low serum and glucose conditions, or both,
chloroquine inhibited HT-1080 growth at even 25 µM concentration (27b – 27d). These
findings were also recapitulated in KP cells as well (data not shown). To confirm that
these results were not due to off-target effects of chloroquine, we repeated the HT-1080
proliferation assay using an independent autophagy inhibitor, Bafilomycin A64. At
nanomolar concentrations, Bafilomycin A treatment mimicked chloroquine treatment in
HT-1080 cells, reducing cell growth at lower drug concentrations under stress conditions
(Fig. 27e – 27h)
To additionally confirm that chloroquine was inhibiting autophagic processes in
our STS cells, we analyzed protein levels of the autophagy readouts p62 and LC3 in HT1080, KP and KIA cells. Consistent with autophagy inhibition, chloroquine treatment
increased p62 abundance, as well as the phosphatidylethanolamine-conjugated form of
LC3, LC3-II 116(Fig. 28a). Furthermore, in HT-1080 cells expressing an LC3-GFP
construct117, chloroquine treatment increased LC3 punctae size in cells under replete
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conditions (Fig. 28b), and punctae sizes was also enhanced upon either oxygen or
serum/glucose depravation (Fig. 28b – 28c). LC3 punctae were similarly larger upon
bafilomycin A treatment, however there was no further significant increase in punctae
size upon low serum/glucose depravation. (Fig. 28d). Together, these data suggest that
soft tissue sarcoma cells are further sensitized to chemical inhibitors blocking autophagy
under tumor-like stresses of low oxygen and nutrient availability.

ATG7 Knockdown phenocopies pharmacologic inhibition of autophagy in fibrosarcoma
cells

Since autophagy inhibitors have side effects that may impact cellular processes
outside of the autophagic pathway, we next decided to directly inhibit processes involved
in autophagy. We employed shRNAs targeting ATG7 mRNA, which encodes a protein
that has a pivotal role in the conjugation of LC3 to phosphatidylethanolamine through the
ATG5-ATG12 complex118,119. ATG7 shRNA achieved robust knockdown at both the
mRNA and protein level in HT-1080 cells (Fig. 29a). Knockdown of ATG7 in HT-1080
cells increased p62 protein accumulation, as well as reduced overall LC3 expression
(Fig. 29a) Under hypoxic and ischemic-like stress conditions (similar to the conditions in
Fig. 27a – 27d), HT-1080 cells lacking ATG7 showed increased cell death, as
demonstrated by Annexin/PI staining (FIG 29b). Taken together, ATG7 knockdown in
fibrosarcoma cells recapitulated the phenotype of the pharmacologic inhibitors
chloroquine and bafilomycin A, suggesting that the phenotypes observed are through
autophagic inhibition, as opposed to off target effects.
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Loss of HIF-1α enhances sensitivity to autophagy inhibition

We next wished to define HIF-1α’s role in autophagy in STS, and whether HIF-1α
affects the sensitivity of cells to autophagic inhibitors. We first determined if BNIP3L, a
hypoxically induced pro-autophagic protein which was overexpressed in hypoxic STS
patient samples6,66, was regulated by HIF-1α in UPS cells. Indeed, when KIA UPS cells
were grown under 1% O2 conditions, BNIP3L protein levels were upregulated (Fig. 30a),
and upon shRNA mediated knockdown of HIF-1α, BNIP3L levels were reduced under
1% O2. BNIP3L abundance was not affected by 25 µM chloroquine treatment, however
we noticed HIF-1α protein accumulation under 21% O2 conditions (Fig. 30a, discussed
further below). Since HIF-1α may promote autophagy through BNIP3L, we next
determined if knockdown of HIF-1α would further sensitize STS cells to autophagic
inhibition. Under 21% O2, KIA and KP cells with or without HIF-1α had similar IC50
values to chloroquine (Fig. 30b). However, under 1% O2, HIF-1α deficient cells are more
sensitive to chloroquine treatment than scrambled shRNA control cells (Fig. 30b).
Given our result that chloroquine treatment elevated HIF-1α protein levels under
normoxic conditions, we next wanted to assess if HIF-1α was activating downstream
effector genes, and by what mechanism HIF-1α was being stabilized under these
conditions. Previous studies have suggested that chloroquine treatment increases
reactive oxygen species (ROS) levels in cells120, and in other cell contexts, chloroquine
treatment has been shown to increase HIF-1α levels121. Since elevated ROS levels are
able to stabilize HIF-1α122, we tested whether antioxidant treatment (N-acetylcystine,
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NAC) could reverse HIF-1α stabilization with chloroquine. Upon chloroquine treatment,
we again observed HIF-1α stabilization in another cell line (HT-1080 cells) under 21%
O2. However, this increase was at a much lower level than PBS treated cells under 1%
O2 (Fig. 31a). The addition of 0.5 – 2 mM NAC in chloroquine treated cells reversed the
buildup of HIF-1α under 21% O2, but similar NAC treatment did not affect HIF-1α
accumulation under 1% O2 (Fig. 31a). Furthermore, HIF-1α target genes Ldha and Pgk1
were not elevated in chloroquine treated KIA cells under normoxic or hypoxic conditions
for 6 hours (Fig. 31b). Collectively, these data suggest that under normoxic settings,
chloroquine increases HIF-1α expression due to increased ROS levels, but HIF-1α
cannot promote the transcription of its target genes.

Inhibition of autophagy with chloroquine reduces STS growth in vivo
We next assessed if chloroquine is an effective treatment in slowing UPS growth
in vivo. Once UPS allografts of KIA cells reached approximately 100 mm3, mice were
treated with PBS control or chloroquine at 60 mg/kg/day115. Chloroquine significantly
inhibited KIA tumor growth (Fig. 32a), as well as reduced tumor weights at time of
sacrifice (Fig. 32b). To determine if autophagy was inhibited in KIA tumors in the
chloroquine treated mice, we measured p62 protein levels and found increased p62
expression in chloroquine treated compared to PBS treated animals (Fig 32c).
We established whether the tumor growth difference was due to increased
apoptosis, decreased proliferation or both. Expression of cleaved-caspase-3, a marker
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of apoptosis, was elevated in chloroquine treated tumors at the protein level and by
immunohistochemical staining (Fig. 32d). However, proliferation, as marked by Ki67+
cells, was not significantly different between PBS and chloroquine treated tumors (Fig.
32e). We also treated KP (UPS) allografts with chloroquine at the same dose as KIA
tumor bearing mice. Similar to KIA tumors, chloroquine treatment significantly slowed KP
tumor growth in vivo (Fig. 33a), as well as lowered tumor weights at time of sacrifice
(Fig. 33b). These data show that inhibiting autophagy in vivo significantly reduces UPS
tumor growth, through increasing the apoptotic rate in tumors.
The autophagy inhibitor Lys05 potently inhibits STS growth in vitro and in vivo.
The chloroquine derivative hydroxychloroquine has been investigated in
combination with other cancer therapeutics in a number of clinical trials in multiple
different cancer subtypes123. However, due to dose-limiting toxicity of this drug, it has
been difficult to achieve consistent autophagic inhibition in patients’ tumors, at least in
the drug combinations analyzed. Therefore, new autophagy inhibitors more potent than
chloroquine are under development. One such inhibitor currently under investigation is
Lys05115. We first assessed Lys05’s IC50 in our STS cell lines in vitro. Lys05 had a lower
IC50 than chloroquine (Fig. 34a – 34c) in HT-1080, KIA, and KP cell lines in all four
growth conditions tested (compare to Fig. 26a – 26c). In particular, under ischemic-like
conditions, the Lys05 IC50 was greatly reduced to 0.9 nM, 0.22 nM, and 0.15 nM in HT1080, KIA, and KP cells respectively.
Next, we assessed whether Lys05 was effective in vivo in fibrosarcoma and
UPS cells. Following a previously established dosing schedule115, we treated mice
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with 60 mg/kg of Lys05 (similar to chloroquine) for three consecutive days, followed by a
two day drug holiday. HT-1080 xenograft tumor size was significantly inhibited in Lys05
treated mice (Fig. 35a). At sacrifice, the tumor weights of mice receiving Lys05 was 0.15
grams, compared to 0.28 grams in the PBS control treated mice (Fig. 35b). In addition,
there was no significant weight change over the treatment course in mice receiving
either PBS or Lys05 (Fig. 34c). Similarly, in mice bearing KIA and KP allografts, Lys05
treatment with the same dosing schedule significantly reduced tumor growth (Fig. 35d)
and tumor weights (Fig. 35e). Collectively, these data suggest that autophagic inhibition
with Lys05 can significantly reduce fibrosarcoma and UPS growth in vivo even when
administered in a more permissive schedule than chloroquine.

Discussion:
Given the low response rates to standard of care chemotherapeutics in
unresectable and metastatic soft tissue sarcoma71,72, there is a pressing need for new
therapeutic regimens in treating this aggressive disease. Newer targeted therapeutics
are currently being evaluated102,124, and by using a rational approach with these drugs to
inhibit the precise molecular processes driving specific STS subtypes, better patient
outcomes will hopefully be achieved. In sarcomas, several preclinical studies have
identified specific subtypes that respond to autophagic inhibition, often in combination
with other targeted therapeutics67,68.
In this study, we show that fibrosarcoma and UPS cells are sensitive to
chloroquine treatment as a monotherapeutic in vitro, and this sensitivity is enhanced
under conditions of hypoxia (1% O2) and ischemic-like stress (reduced serum and
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glucose concentrations in the growth media). These results were recapitulated in
bafilomycin A treated cells, as well as with shRNA mediated ATG7 knockdown. Our data
suggest that HIF-1α promotes autophagy in UPS cells in vitro, as loss of HIF-1α
increased the sensitivity to chloroquine. Interestingly, we observed increases in HIF-1α
protein levels upon chloroquine treatment under normoxic conditions in vitro, however
downstream HIF-1α target genes were not upregulated.
In vivo, daily treatment of mice with chloroquine bearing STS tumors showed
significant reduction in tumor growth due to increased levels of apoptosis, without any
gross changes in overall weight. Additionally, we tested Lys05, a more potent inhibitor of
autophagy than chloroquine, in our STS cell lines in vitro and in vivo. We observed
significant reduction of allograft and xenograft growth with this compound, even with a
treatment schedule that included drug holidays. These results suggest that autophagic
inhibition through use of Lys05 merits further clinical investigation in the STS subtypes
analyzed herein, and may be of potential therapeutic benefit in these patient populations.
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Chapter 4: Concluding Remarks
The previous two chapters have introduced two distinct, but interconnected
pathways that are present in several high-grade soft tissue sarcomas, the hypoxic
response (chapter 2) and autophagy (chapter 3). In chapter 2, I showed that EPAS1
expression was lost in human STS samples, and that knockdown or loss of HIF-2α
accelerated the growth of UPS, fibrosarcoma, and dedifferentiated liposarcoma in vivo.
In both UPS and liposarcoma, I demonstrated that loss of HIF-2α increased mTORC1
signaling. In UPS, HIF-2α deficient tumors showed increased ANO1 accumulation, which
increased CAMKII phosphorylation and in turn promoted mTORC1 activation.
Additionally, I established that EPAS1 could be re-expressed through epigenetic
modifying agents. Specifically, class I and II HDAC inhibitors like SAHA (Vorinostat)
increased HIF-2α, but not HIF-1α, expression. SAHA inhibited STS growth as a
monotherapeutic, both in vitro as well as in vivo. Interestingly, I showed that SAHA’s
anti-tumor effect in STS was predominantly due to HIF-2α being re-expressed, as
knockdown or deletion of HIF-2α prevented SAHA from affecting tumor growth. In
chapter 3, I demonstrated that autophagy plays an important role in STS survival under
stress conditions. Under ischemic-like conditions, fibrosarcoma and UPS cells show
increased sensitivity to pharmacologic inhibition of autophagy, which was recapitulated
with ATG7 knockdown. Also, HIF-1α loss increased sensitivity to autophagic inhibition in
vitro. I confirmed that autophagic inhibition with chlorquine reduced fibrosarcoma and
UPS tumor growth in vivo, and a more potent autophagic inhibitor, Lys05, demonstrated
similar effects but with fewer drug treatments over the time course analyzed. Taken
together, these studies add to our understanding of the progression of mesenchymal
tumors, and illustrate potentially new therapeutic options for patients with this disease.
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Here, I will address some of the broader implications that arise from this body of work,
as well as suggest future studies to build upon these ideas.
Hypoxic responses in STS
Hypoxia is a common feature in several STS4, and is associated with a worse
prognosis in patients. Therefore, understanding how hypoxia, its cellular sensors HIFs,
and downstream effectors work is important in this tumor context. Clinically,
understanding each HIFα’s effect in different cancer contexts is important, as the
development of hypoxia-induced drugs125 and HIF inhibitors80,126 continues. While we
and others have demonstrated that HIF-1α and HIF-2α can have different, if not opposite
roles in distinct cancers such as clear cell renal cell carcinoma21 (ccRCC) and non-small
cell lung cancer23, the data presented in chapter 2 of this dissertation comprises the first
attempt of characterizing HIF-2α’s role in STS and demonstrating that it opposes STS
growth in the subtypes examined. However, the majority of HIF inhibiting compounds are
not completely selective for one specific isoform. These inhibitors range in their specific
mechanisms of action. For example, some HIF inhibitors block transcriptional activity
and DNA binding through inhibiting dimerization of HIFα with ARNT127, or by inhibiting
p300 recruitment128. Other HIF inhibiting drugs indirectly affect HIF-1α translation, often
through pathways that impinge on the HIF pathway (i.e. blocking mTOR129 or
EGFR/PI3K pathway130). Therefore, a complete understanding of both HIFα’s role in a
specific cancer is essential before these pan-HIFα inhibiting compounds are tested
clinically.
However, a HIF-2α specific inhibitor was recently developed as a potential
therapeutic in ccRCC79, a malignancy where HIF-2α is pro-tumorigenic131. This
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compound specifically binds to a hydrophilic cavity inside HIF-2α, disrupting the HIF2α/ARNT heterodimer. Importantly, the similar pocket in HIF-1α is smaller than in HIF2α, preventing the drug from inhibiting the HIF-1α/ARNT heterodimer79. Recently, the
crystal structures of both HIF-α/ARNT heterodimers have been resolved, confirming the
location where this drug inhibits HIF-2α/ARNT binding132.
Now that the crystal structure of the HIF-α/ARNT heterodimers has been
resolved, hopefully other areas of the HIF-1α/ARNT interaction can be specifically
targeted in a similar way as HIF-2α/ARNT. Using datasets of cancer mutations such as
COSMIC to probe sites of HIF-1α where mutations are common, we may discover more
specific and effective therapeutics specifically against this transcription factor. HIF-1α
specific inhibitors could be very beneficial to STS patients, as they would prevent the
pro-metastatic effects of HIF-1α24 without affecting the anti-growth property of HIF-2α
described here. These inhibitors could also be tested on the variety of STS mouse
models that exist for different subtypes.
Besides direct HIF inhibition, data from chapter 2 of this dissertation suggest that
epigenetic modifying drugs may be useful in modulating HIF levels in this disease. In the
context of the STS subtypes analyzed, our work suggests that histone deacetylation
silences HIF-2α expression, and by therapeutically inhibiting this process with HDAC
inhibitors, HIF-2α can be re-expressed. It would be interesting to characterize HIF-2α
expression changes upon HDAC inhibition in different tumor contexts, especially in
malignancies where HIF-2α has shown to be tumor suppressive22,23. Furthermore, we
observed that longer treatment courses of the HDAC inhibitor SAHA led to resistance,
with Epas1 expression levels not significantly increased compared to controls (Fig. 19a).
One intriguing possibility is that the Epas1 locus is becoming epigenetically silenced
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through a different mechanism upon HDACi treatment, such as through histone or DNA
methylation. Combining HDACi and histone methylation/DNA methyltransferase
inhibitors in STS and observing long-term changes in Epas1 could address this question.
In chapter 2, we used two separate HDAC inhibitors, SAHA and Trichostatin A,
which both inhibit multiple class I and class II HDACs in cells87,133. It would be interesting
to determine which HDAC(s) specifically are involved in deacetylating the EPAS1 locus
in STS, by systematically knocking down expression of each HDAC in STS cells using a
shRNA mediated approach. Knowing which specific HDAC is responsible for
deacetylating EPAS1 is important, since newer HDACi are being developed that are
more selective in which HDAC they block111.
An interesting result in chapter 2 that requires future study is how EPAS1 mRNA
abundance affects HIF-2α protein levels in the STS cells analyzed. Currently, the HIFα
subunits are thought to be mainly regulated through post-translational mechanisms (e.g.
hydroxylation and degradation by the PHD family of enzymes)12. But, SAHA treatment
increased mRNA expression of EPAS1 only two to five fold in STS cells, and yet an
increase in HIF-2α protein abundance was observed. This increase in HIF-2α protein
may potentially be due to off target effects of SAHA. Knockdown of specific HDACs with
shRNA (as mentioned above) and observing whether there are changes in HIF-2α
protein levels may help address this question. However, the increase in HIF-2α protein
may also be due to increased EPAS1 transcript levels in STS cells, in which the
translate protein levels are amplified to a point at which the normal post-translation
regulation and degradation machinery cannot function properly. Understanding the state
of these regulators (e.g. PHDs, FIH) in STS is important, because it may potentially offer
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another druggable target in which HIF-2α protein levels can be increased in these
malignancies.
Another direction of future research will be to investigate whether HIF-2α loss
affects sarcomagenesis, and at which stage of development. Currently, there are several
different theories as to what molecular pathways control sarcomagenesis in different
sarcoma subtypes. For high-grade, poorly differentiated/dedifferentiated sarcomas,
altered Wnt signaling has been one proposed as a mechanism of transformation. Some
groups have proposed that inhibiting Wnt signaling in mesenchymal stem cells (MSC)
can give rise to UPS134, while others show that Wnt signaling is increased in several
different STS cell lines in vitro135. However, a lack of a relevant in vivo model in which
sarcomagenesis can be spatially and temporally tracked has made it difficult to answer
these questions.
Additionally, the role of HIFs in sarcomagenesis has also not been addressed.
Although it may seem unlikely that the HIFα’s affect the early stages of tumor initiation,
as very hypoxic/ischemic areas likely have not developed, in certain tissues of the body
(e.g. renal medulla, skeletal muscle), low oxygen tension can be present
physiologically12. As demonstrated in chapter 2 of this dissertation, loss of HIF-2α in STS
in vivo led to faster tumor growth of fibrosarcoma and dedifferentiated liposarcoma
xenografts, as well as faster development of macroscopically visible UPS tumors in the
autochthonous mouse model. However, since the xenografts were of already
transformed cells, and the autochthonous tumors could only be assessed once
macroscopically visible, the question of HIF-2α’s function during the initiating stages of
sarcomagenesis remains unknown.
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To help address the question of HIF-2α’s role in sarcomagenesis, we are
currently generating an autochthonous mouse model that generates UPS tumors in
muscle satellite cells136. These mice have the background of Pax7CreER-LSLKrasG12D/+Trp53fl/fl (Pax7KP) and Pax7CreER-LSL-KrasG12D/+Trp53fl/flEpas1fl/fl
(Pax7KPH2). Upon tamoxifen treatment, Pax7KP mice should generate UPS tumors in
approximately seven to eight weeks136. Unlike the autochthonous model described in
chapter 2 of this dissertation, the cell of origin of the UPS tumors is specifically a Pax7+
muscle satellite cell. Therefore, Pax7+ muscle satellite cells can be isolated from the
mice, and after ex vivo administration of tamoxifen, we can study any changes in
molecular pathways in these cells. Furthermore, we are interested to observe if
Pax7KPH2 form more tumors (or tumors more quickly) compared to Pax7KP mice. We
will be interested in assessing if Wnt signaling affects sarcomagenesis in this model, and
whether HIF-2α deletion alters the Wnt pathway. However, we will also attempt an
unbiased RNA-seq based approach to determine if other pathways are altered in
sarcomagenesis, with or without HIF-2α present.
Finally, although we showed in chapter 2 that loss of HIF-2α increased Ano1
expression, the specific mechanism remains unclear. We postulated that the mechanism
is through Myc, since loss of HIF-2α increased Myc protein levels (Fig. 11a), and ChIPseq data of breast and leukemia cells shows Myc binding near the ANO1 promoter. We
hypothesize that HIF-2α loss increases Myc, because previous reports have shown that
the HIFs promote degradation of Myc under hypoxic conditions137. Furthermore, while
Myc targets individually were not differentially expressed in KP versus KPH2 tumors,
overall they trended towards Myc activation (Fig. 11a). Preliminary data in KPH2 cells
showed that treatment with 500 nM of JQ1, a potent inhibitor of the BET family of
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bromodomain proteins that also reduces Myc expression138, reduced both Myc as well
as Ano1 protein levels (data not shown). mRNA levels of Ano1 and Camk2a (encoding
CAMKII) also significantly decreased upon treatment with JQ1 (data not shown). Further
studies are necessary to prove this hypothesis, such as measuring Myc degradation rate
in HIF-2α deficient versus HIF-2α expressing UPS cells, as well as performing ChIP of
Myc on putative Myc binding sites in the Ano1 promoter. If Myc does in fact connect loss
of HIF-2α promoting Ano1 expression, Myc may be another potential therapeutic target
in this disease, and potentially other cancers where Ano1 overexpression promotes
tumor growth96.
Autophagy and Sarcoma
In chapter 3, I established that autophagy plays an important role in cell survival
under stress conditions in fibrosarcoma and UPS in vitro and in vivo. Grown under in
vitro conditions mimicking hypoxia or ischemia, the STS cell lines examined showed
increased sensitivity to autophagy inhibition, either pharmacologically with chloroquine
and bafilomycin A, or through knockdown of ATG7, a critical mediator of autophagy.
Knockdown of HIF-1α increases chloroquine sensitivity in UPS cells in vitro.
Interestingly, I noticed that chloroquine treatment stabilized HIF-1α under normoxic
conditions in vitro, which was reversed with antioxidant treatment. However, HIF-1α did
not activate downstream target genes under this condition. This result contrasts to
previous reports in HeLa cells which show increased HIF-1α target gene expression
upon bafilomycin A and chloroquine treatment139. This may be due to cell context
differences, or that HeLa cells were treated with higher doses of autophagy inhibitors
than were examined here. Additionally, chloroquine treatment reduced STS tumor
growth in vivo by increasing apoptosis in STS xenograft and allografts. Finally, Lys05, a
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newer and more potent inhibitor of autophagy than chloroquine115, also reduced STS
tumor growth in vivo.
It will be important to define autophagy’s relevance to STS in patients.
Unfortunately, thorough sarcoma clinical datasets encompassing multiple subtypes with
expression data and patient outcome are only beginning to be compiled, such as The
Cancer Genome Atlas. Currently, most sarcoma datasets have expression data on
tumors without survival outcomes. Therefore, it is difficult to determine from prior data
whether higher or lower expression of autophagic genes confers a survival advantage or
disadvantage in fibrosarcoma or UPS patients. In addition, while BNIP3L and other
autophagic markers may be upregulated in sarcomas, it remains to be determined if their
expression can serve as a biomarker for sensitivity to autophagy inhibitors.
As mentioned in chapter 3, chloroquine (or hydroxychloroquine) has been tested
in mouse models and cancer patients as a pharmacologic inhibitor of autophagy. In preclinical studies in mice, chloroquine has shown to effectively inhibit autophagy in several
different tumor types, and reduce the tumor burden123. However, in order to reliably
inhibit autophagy in patients, the dosage of chloroquine required is often too toxic and
inconsistently achieved123. Therefore, more potent and/or less toxic autophagy inhibitors
need to be developed to achieve reliable autophagic inhibition without the dose limiting
side effects.
Lys05, a derivative of chloroquine with two aminoquinoline rings115, was designed
to be a more potent autophagy inhibitor than chloroquine. Results from chapter 3 of this
dissertation (Fig. 34a – 34c) show Lys05 has a lower IC50 in fibrosarcoma and UPS cells
compared to chloroquine in vitro. Lys05 was also able to reduce tumor growth in vivo
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(Fig. 35). While chloroquine was administered daily, Lys05 inhibited tumor growth with a
two day drug holiday after 3 days of treatment. These results suggest that Lys05 is more
potent than chloroquine, but the question remains as to whether Lys05 at these lower
doses is actually less toxic and has fewer side effects than chloroquine. Future work will
continue to analyze the effect of Lys05 treatment on the fibrosarcoma and UPS tumors
we generated, and whether its effect on tumors was due to increasing apoptotic rates
(similar to chloroquine), or reduced proliferation of tumors. Additionally, we will examine
markers of autophagic inhibition in Lys05 tumors (e.g. LC3-II and p62 protein
accumulation) to see if the drug was able to consistently block autophagy. In addition,
these in vivo studies were performed in xenograft and allograft models, and may not fully
recapitulate the complete tumor microenvironment seen in patients. Therefore, further
studies using Lys05 in the autochthonous UPS model (KP model) are warranted. Future
clinical trials testing Lys05 in sarcoma patients will address the toxicity profile of the
drug, and hopefully recapitulate results from our mouse models.
Another potential direction of future study would be to combine autophagy
inhibition with other therapeutics. Since it has been demonstrated that autophagy can be
activated by stress from chemotherapeutics in several different tumor cell types140,
combining traditional chemotherapeutics with Lys05 may augment tumor cell death.
Indeed, in epithelial cancers such as breast141 and colon cancer142, combining
chemotherapies with chloroquine or ATG7 knockdown increased tumor suppression. For
the high grade STS subtypes examined in this dissertation, doxorubicin is the standard
of care chemotherapeutic. Given the results in epithelial cancers, further studies
combining doxorubicin and Lys05 may be warranted for STS.
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Another potential therapeutic combination with autophagy inhibitors is using
HDAC inhibitors, as it has been shown that HDAC inhibitors can induce autophagy in
certain contexts143. In one subtype of sarcoma, malignant peripheral nerve sheath
tumors, combining chloroquine with HDACi enhanced apoptotic cell death67. HDACi with
Lys05 has yet to be tested in fibrosarcoma or UPS, but could prove to be an attractive
therapeutic combination.
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MATERIALS AND METHODS
Cell Culture:
HT-1080 (fibrosarcoma) and HEK-293T cell lines were purchased from ATCC
(Manassas, VA, USA). KIA, KP210, KP230, and KP250 cell lines were derived from UPS
mouse tumors83. These high-grade neoplasms showed myofibroblastic differentiation
and atypical nuclei, and by expression profiling matched human MFH/UPS. LPS246 was
established from a primary dedifferentiated liposarcoma sample (confirmed with MDM2
FISH analysis), and was provided by Dr. Dina Lev (Core Facilities, MD Anderson Cancer
Center, Houston, TX)144. These high-grade neoplasms showed myofibroblastic
differentiation and atypical nuclei83, and by expression profiling matched human
MFH/UPS82. Cells were grown in DMEM (Corning), 2 mM glutamine, 100 units/ml
penicillin, and 10% FBS (Gemini Biosystems).
KP and KPH2 tumor cells were isolated from primary KP and KPH2 UPS tumors,
respectively. Briefly, UPS were harvested from mice, and transferred to a cell-culture
hood and cut into tiny pieces on a petri dish. Tumors were digested using collagenase
(StemCell #07902, Vancouver, Canada) for 1 hour at 37o C. DMEM/F-12 (Sigma-Aldrich)
with 2% FBS was then added, and the digested mixture was filtered through a 40-micron
filter. Red blood cells were lysed with ACK lysis buffer (Lonza, Allendale, NJ) according
to the manufacturer’s protocol. Cells were pelleted down, and washed with DMEM/F-12.
Cells were cultured in DMEM (Cellgro, Manassas, VA) supplemented with 10% FBS and
incubated at 37°C with 5% CO2 in a humidified cell-culture incubator. Cells were cultured
at least 4 passages before being used for experiments, and Epas1 recombination status
was detected through PCR. All cell lines were negative for mycoplasma contamination.
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Hypoxia:
Hypoxia (either 0.5% or 1% O2) was achieved using a Ruskinn InVivO2 400
workstation. KP and KPH2 tumor derived cell lines were grown and maintained at 3% O2
in a Hera Cell 240 (ThermoFisher Scientific) incubator, until experiments were performed
on the cells at the stated oxygen levels.
Mouse Models
KPH2 mice were generated by crossing KP mice (LSL-KrasG12D/+Trp53fl/fl)83 and
Epas1fl/fl mice88, and KPA mice were generated by crossing KP mice and Arntfl/fl mice145.
KP, KPH2, and KPA mice are on a mixed 129/C57BL/6 background. Tumors were
generated in 8 weeks or older mix of male and female KP, KPH2, and KPA mice by
injecting adenovirus expressing Cre-recombinase (Ad-Cre) into the right hind limb
musculature as previously described83. KP, KPH2, and KPA mice were sacrificed either
7 weeks after Ad-Cre injection, or when tumors reached the maximal permissible size.
Mice were injected with BrdU (Sigma-Aldrich) 30 minutes before sacrifice. For HT-1080
xenografts, 1x106 cells were injected into both flanks of male Balb/c nu/nu mice (Charles
River Laboratories, Wilmington, MA, USA). For KIA and KP250 allografts, 1x106 cells
were injected into both flanks of female nu/nu mice (Charles River Laboratories). For KP
and kPH2 allografts, 7.5x105 cells were injected into both flanks of female nu/nu mice
(Charles River Laboratories). To generate LPS246 xenografts, 2x106 cells were injected
into the flanks of scid/hairless (SHO) mice (Charles River Laboratories). Mice were
injected with control tumors (Scrambled shRNA) in one flank and experimental tumors
(HIF-2α shRNA) in the other for LPS246 and HT-1080 xenografts. Tumor size was
measured every other day (except for cholorquine, Lys05, and SAHA studies, where
84

tumors were measured daily), and animals were euthanized after 14 – 50 days posttumor injection. Researchers were not blinded to the experimental groups during in vivo
treatments. Animal well-being and comfort were monitored by certified veterinary staff.
All mouse experiments were performed according to National Institutes of Health
guidelines and approved by the University of Pennsylvania Institutional Animal Care and
Use Committee. Sample size for each experiment was estimated using the formula n =
((zα/2 σ)/E)2, with α = 0.05, and σ and E based off of initial HT-1080 xenograft
experiments with scrambled and HIF-2α shRNA. No inclusion/exclusion criteria
parameters were used in our studies. All tumors and animals used in experiments were
included in data analysis.
Immunoblotting
Protein lysates were prepared in RIPA lysis buffer, and separated on 10% SDSPAGE gels by electrophoresis. Subsequently, the lysates were transferred to
nitrocellulose membranes and probed with the following antibodies and concentrations:
HIF-2α 1:1000 (Novus #NB100-122), caspase-3 1:1000 (Cell Signaling #9662 Danvers,
MA, USA), GAPDH 1:2000 (Cell Signaling #2118), phospho-4E-BP1 1:1000 (S65,
#9451), 4E-BP1 1:1000 (Cell Signaling #9452), phospho-S6K1 1:1000 (T389, Cell
Signaling #9205), S6K1 1:1000 (Cell Signaling #2708), phospho-AKT 1:1000 (S473, Cell
Signaling #9271), AKT 1:1000 (Cell Signaling #9272), ANO1 1:500 (Abcam ab64085),
phospho-CAMKIIα 1:1000 (T286, Cell Signaling #12716), CAMKII 1:1000 (Cell Signaling
#11945) ATG7 1:1000 (Sigma-Aldrich #A2856) BNIP3L 1:1000 (R&D Diagnostics
AF4030) LC3 1:4000 (Cell Signaling #2775) p62 1:1000 (MBLI #PM045), β-tubulin
1:1500 (Cell Signaling #2146).
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Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated from cells using the TRIzol reagent protocol (Invitrogen)
and from tumors and skeletal muscle tissue using the RNAeasy minikit (Qiagen). RNA
was reverse transcribed using the High-Capacity RNA-to-cDNA kit (Applied Biosystems),
and transcript expression was determined by quantitative PCR using the Applied
Biosystems Viia7 system. Target cDNA levels were measured with Taq-Man
primer/probe sets (Applied Biosystems) for the following mouse and/or human targets:
EPAS1, HIF1A, SERPINE1, MYC, CCND1, CCND2, MCM5, CDKN1A, LDHA, PGK1,
ATG7. Expression levels were normalized to HPRT and ACTB for each sample.
Immunohistochemistry and immunofluorescence
For chapter 2, immunohistochemistry and immunofluorescence were performed
on 5-µm paraffin embedded tissue sections. For immunohistochemistry, enzymatic
Avidin-Biotin Complex-diaminobenzidine staining (Vector Labs) was used with
hematoxylin used for counterstaining nuclei according to standard protocols.
Immunohistochemistry was performed on soft tissue sarcoma and normal arterial and
skeletal muscle tissue array (US Biomax, Rockville, MD, USA #SO801a). The following
primary antibodies and concentrations were used for immunohistochemistry: anti-BrdU
1:40 (Abcam #ab6326), anti-cleaved caspase-3 Asp 175 1:300 (Cell Signaling #9661)
anti-Ki67 1:100 (Abcam #ab15580), anti-phospho-S6 (S235/236, Cell Signaling #4858),
anti-HIF-2α (ThermoPierce #PA1-16510). The following primary antibodies and
concentrations were used for immunofluorescence: anti-CD31 1:50 (Abcam #ab28364),
anti-pimonidazole FITC 1:100 (Hypoxyproble HP2). Mounting media with DAPI (Life
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Technologies #P36935) was applied last. Sections were imaged using a Leica DMRB
microscope and an Olympus DP72 camera.
For chapter 3, stably transfected HT-1080 LC3-GFP cells, maintained in media
with puromycin, were grown on pre-collagen treated slide covers and exposed to drug or
PBS for 6 hours. At the end of the 6 hours the cells were treated with 3%
paraformaldehyde and DAPI. The slide covers were than mounted onto a microscope
slide and treated with Prolong Gold Antifade Reagent (ThermoFisher Scientific). Cells
were imaged using a Leica DMRB microscope and an Olympus DP72 camera.
Proliferation Assay
For chapter 2, cells were plated in triplicate for each data point, and incubated
overnight in tissue culture dishes. The following day, DMSO or SAHA, diluted in growth
media, was added to the cells, and the cells were place either in normoxic conditions
(21% O2) or hypoxic conditions (1% O2). Media with drug was changed every two days.
Cells were trypsinized, resuspended in PBS, and counted using a hemocytometer on the
days indicated.
For chapter 3, cells were plated in triplicate for each data point, and incubated
overnight in tissue culture dishes. The following day, PBS or drug (CLQ, Bafilomycin A1,
or Lys05), diluted in growth media, was added to the cells at the indicated
concentrations. Then, the cells were place either in normoxic conditions (21% O2) or
hypoxic conditions (1% O2). Media with drug was changed every two days. Cells were
treated with WST-1 cell proliferation reagent (Sigma-Aldrich) and quantified using a plate
reader following the manufacturer’s protocol at 450 nm at the end of the experiment.
Migration Assay
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Migration assays were performed using 24-well chambers with inserts (8-µm pores) (BD
Biosciences). Medium containing 10% serum was placed in the lower chamber, and
tumor cells (1 × 105) suspended in medium without serum were added to the top
chamber. The plates were incubated under 21% or 1% O2 for 16 hours. After migration,
nonmigratory cells were removed from the top of the insert membrane using cotton
swabs. The underside of each membrane was fixed in Methanol and stained with DAPI
(Invitrogen), and the number of cells that migrated completely through the 8-µm pore
was determined in 10 random high-power fields (20x objective) for each membrane.
Cytotoxicity Assay
Cytotoxicity Assays 5×104 cells in 200 uL of media were plated in each of 80 wells of a
96 well plate on the day prior to drug exposure. Cells were exposed to serial
concentrations of chloroquine (Sigma-Aldrich), or Lys05 in complete media under 21%
O2 or low serum (1% FBS)/low glucose (1mM) DMEM media under 1% O2. The media
was exchanged for drug-free complete or equilibrated SG media following 24 hours of
incubation. The media was again exchanged for complete media at 48 hours of
incubation. Following 72 hours of incubation, cellular viability was measured using the
CytoScan WST-1 Assay (G-Biosciences, St. Louis, MO). Spectrophotometric measures
of absorbance were made using a SpectraMax M2e microplate reader (Molecular
Devices, Sunnyvale, CA).
Chromatin Immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) assays were performed using QuickChIP
assay kits (Novus Biologicals). Briefly, five million KP250, KP, or KPH2 cells grown at
the indicated oxygen level were fixed in 1% formaldehyde for 10 minutes at 37oC, and
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the reaction stopped by glycine. Cells were washed, collected, and lysed using SDS
buffer containing protease inhibitor cocktail, and then sonicated into DNA fragments of
300-800 bp in size. Supernatants were diluted and pre-cleared with salmon sperm
DNA/protein A/G agarose, and a 10 µl aliquot was saved for input control. The rest of the
sample was immunoprecipitated with 5 ug of the following antibodies overnight: Rabbit
IgG (Cell Signaling), Histone H3 (Abcam), Histone H3 Acetyl K9+K14+K18+K23+K27
(Abcam). Antibody-nucleoprotein complexes were recovered by incubating 60 uL of
salmon sperm DNA/protein A/G agarose for 1 hour at 4oC with rotation. Beads were
washed and antibody-nucleoprotein complexes were eluted from protein A/G agarose
beads in elution buffer, de-crosslinked by adding 20µL 5M NaCl and incubated at 65oC.
Subsequently, RNAase A and proteinase K were added, and DNA fragments were
purified using QIAquick PCR purification kit (Qiagen). Semi-quantitative PCR was
performed with the following primers: Epas1 Forward: 5’CATTACTCAGTCCTGCGCTAACTG-3’; Epas1 Reverse: 5’CTCAGGACACTGCCGAGGATTGTA-3’; Hif1a Forward: 5’AATCACTTGGAGACTTCCCTTGTT-3’; Hif1a Reverse:
5’CACGTTGCTCTCAGCCAATCAGGA-3’.
Oncomine Study Design
We used publically available databases through Oncomine Research Premium
edition software (version 4.5, Life Technologies) to query HIF-2α expression and survival
data in sarcomas relevant to our study. For expression data, we used the Barretina et.
al.89 and Gobble et. al.90 datasets, and for survival data the Gobble et. al. dataset was
analyzed.
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Survival Analysis
Available patient survival data was obtained from Gobble et al. dataset for
liposarcoma patients through Oncomine. Patients were divided into 2 groups: tumors
expressing the highest 50% of EPAS1 ‘High EPAS1’ and lowest 50% ‘Low EPAS1’, and
Kaplan-Meier survival analyses were performed for overall survival of patients.
CT Imaging
Computer tomography (CT) images were generated using an Imtek MicroCAT II
microCT scanner. The settings for the scan were 80 kVp, 500 uA with a 375 ms
exposure time per projection. 360 projections were taken for the scan lasting
approximately 6 minutes. Reconstruction was performed with the software provided with
the scanner: MicroCAT: Image Reconstruction, Visualization, & Analysis. It used a
Feldkamp Reconstruction with a Shepp-Logan Filter. Voxel size is 103 µm x103 µm x
103 µm. Tumor volume was measured from scans using Amide software, and
measurements were confirmed by a board-certified radiologist who was blinded to the
treatment given to each mouse.
RNA-seq
RNA was extracted from KP and KPH2 FFPE tumor sections using RNeasy
FFPE kit (Qiagen #73504). Library preps and RNA-seq were performed by the Next
Generation Sequencing Core at the University of Pennsylvania, using TruSeq Stranded
Kit (Illumina #RS-122-2201), Ribo-Zero Gold Kit (Epicentre #MRZG126) and an HiSeq
100SR (Illumina). Raw sequence and quality files were aligned to the mouse genome
(GRCm38) using the RNA alignment tool STAR (version 2.4,
https://code.google.com/p/rna-star/). Unique transcript alignments were counted for each
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sample using htseq-count (version 0.6.1, http://wwwhuber.embl.de/users/anders/HTSeq/doc/count.html) against the RefSeq transcripts for
GRCm38, yielding counts for 26,667 transcripts for each sample. Principle Components
Analysis of raw count data revealed that one HIF-2α knockout sample was a technical
outlier. This sample was excluded from statistical analysis.
Differential expression and gene set enrichment analysis
Transcript count files for 3 HIF-2α knockout samples and 4 wild type samples
were analyzed with DESeq2 (version 1.6,
http://bioconductor.org/packages/release/bioc/html/DESeq2.html) for differential
expression. Log2-transformed, normalized intensities were also exported from DESeq2
for visualization and used as input for Gene Set Enrichment Analysis (see below).
Overall sample relatedness was visualized with Principal Components Analysis (PCA, as
implemented in Partek Genomics Suite v6.6, Partek, Inc. St. Louis, MO) using the
normalized expression intensities for all transcripts. Log2-transformed expression
intensities from these samples were imported into GSEA (version 2.1,
http://www.broadinstitute.org/gsea/index.jsp). Enrichment of gene sets corresponding to
Canonical Pathways (C2-CP from the Molecular Signatures Database v4.0,
http://www.broadinstitute.org/gsea/msigdb/index.jsp) was tested with default settings.
Tables of enriched pathways for genes up in HIF-2α knockout or wild type were
exported, with a FDR < 0.1 cutoff.
TCGA Bioinformatics Analysis
Level 3 data comprising regions with altered copy number and methylation status
in sarcoma were downloaded through the TCGA portal (https://tcga91

data.nci.nih.gov/tcga/tcgaHome2.jsp). Data was analyzed with Partek software (version
6.6). Tumor samples for copy number analysis consisted of 260 primary tumors, 3
recurrent tumors, and 1 metastatic tumor. The results from blood and normal controls
were eliminated from the analysis as they contained no amplifications or deletions.
Briefly, sample files were lined up and concatenated. Thresholds for amplifications and
deletions were set at 0.55 and -0.4, as based on previously published literature.
Methylation analysis was performed on 242 primary tumors, 2 recurrent tumors, 1
metastatic tumor, and 4 normal tissues. Probes annotated for proximity to EPAS1 were
evaluated. All probes were tested for differential beta values between normal and all
tumor samples with ANOVA followed by Benjamini-Hochberg FDR correction.
Ingenuity Pathway Analysis
DESeq2 statistical results for differential expression were uploaded to Ingenuity
Pathway Analysis. Genes with at least a 0.75 log2 ratio (+/- 1.7 fold) and a false
discovery rate corrected p-value of < 0.05 were analyzed. The changes in the subset of
these genes that were known to interact with mTOR were used to predict the activity
changes of MTOR in KPH2 versus KP tumors. Canonical pathway analysis was also
performed, with the top 15 most statistically significant pathways shown (orange bars =
pathway predicted to be more active in KPH2 tumors, blue bars = pathway predicted to
be less active in KPH2 tumors, grey bar = no activity pattern available).
Statistical Analysis
Statistical analysis was performed using Prism (GraphPad Software). Data are
shown as mean + s.e.m. unless otherwise specified. Data were reported as biological
replicates, with technical replicates indicated in figure legends. Unpaired two-tailed
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student t-tests were performed to determine if results were statistically significantly
different, with a p-value cutoff less than 0.05 considered significant. Variation within each
data group was measured with Graphpad Prism software, and found to be similar
between groups tested.
Accession Codes
GEO: GSE67672
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